text,label
"nisoldipine extendedrelease tablets are indicated for the treatment of hypertension they may be used alone or in combination with other antihypertensive agents,",3
"none bisoprolol fumarate tablets usp are indicated in the management of hypertension they may be used alone or in combination with other antihypertensive agents,",3
"pindolol tablets are indicated in the management of hypertension it may be used alone or concomitantly with other antihypertensive agents particularly with a thiazidetype diuretic,",3
"eprosartan mesylate tablets are indicated for the treatment of hypertension they may be used alone or in combination with other antihypertensives such as diuretics and calcium channel blockers,",3
"none labetalol hydrochloride tablets usp are indicated in the management of hypertension labetalol hydrochloride tablets usp may be used alone or in combination with other antihypertensive agents especially thiazide and loop diuretics,",3
"hypertensiontimolol maleate tablets are indicated for the treatment of hypertension they may be used alone or in combination with other antihypertensive agents especially thiazidetype diuretics myocardial infarctiontimolol is indicated in patients who have survived the acute phase of myocardial infarction and are clinically stable to reduce cardiovascular mortality and the risk of reinfarction migrainetimolol is indicated for the prophylaxis of migraine headache,",3
"hypertensionacebutolol hydrochloride capsules usp are indicated for the management of hypertension in adults it may be used alone or in combination with other antihypertensive agents especially thiazidetype diuretics ventricular arrhythmiasacebutolol hydrochloride capsules usp are indicated in the management of ventricular premature beats it reduces the total number of premature beats as well as the number of paired and multiform ventricular ectopic beats and ront beats,",3
"nicardipine hydrochloride capsules are indicated for the management of patients with chronic stable angina effortassociated angina nicardipine hydrochloride capsules may be used alone or in combination with betablockers nicardipine hydrochloride capsules are indicated for the treatment of hypertension nicardipine hydrochloride capsules may be used alone or in combination with other antihypertensive drugs in administering nicardipine hydrochloride it is important to be aware of the relatively large peak to trough differences in blood pressure effect see dosage and administration,",3
"betaxolol hydrochloride ophthalmic solution has been shown to be effective in lowering intraocular pressure and is indicated in the treatment of ocular hypertension and chronic openangle glaucoma it may be used alone or in combination with other antiglaucoma drugsin clinical studies betaxolol hydrochloride ophthalmic solution was safely used to lower intraocular pressure in 47 patients with both glaucoma and reactive airway disease who were followed for a mean period of 15 months however caution should be used in treating patients with severe reactive airway disease or a history of asthma,",3
"terazosin capsules usp are indicated for the treatment of symptomatic benign prostatic hyperplasia bph there is a rapid response with approximately 70 of patients experiencing an increase in urinary flow and improvement in symptoms of bph when treated with terazosin capsules usp the longterm effects of terazosin capsules usp on the incidence of surgery acute urinary obstruction or other complications of bph are yet to be determinedterazosin capsules usp are also indicated for the treatment of hypertension terazosin capsules usp can be used alone or in combination with other antihypertensive agents such as diuretics or betaadrenergic blocking agents,",3
"because of the potential for serious adverse effects minoxidil tablets are indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs at the present time use in milder degrees of hypertension is not recommended because the benefitrisk relationship in such patients has not been definedminoxidil reduced supine diastolic blood pressure by 20 mm hg or to 90 mm hg or less in approximately 75 of patients most of who had hypertension that could not be controlled by other drugs,",3
"benazepril hydrochloride tablets usp are indicated for the treatment of hypertension benazepril hydrochloride tablets may be used alone or in combination with thiazide diureticsin using benazepril consideration should be given to the fact that another angiotensinconverting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagenvascular disease available data are insufficient to show that benazepril hydrochloride tablets do not have a similar risk see warningsblack patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks it should also be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks,",3
"none n hypertension none trandolapril tablets are indicated for the treatment of hypertension they nmay be used alone or in combination with other antihypertensive medication such nas hydrochlorothiazide in considering the use of trandolapril tablets it should be noted that in ncontrolled trials ace inhibitors for which adequate data are available cause a nhigher rate of angioedema in black than in nonblack patients see n warnings angioedema when using trandolapril tablets consideration should be given to the fact nthat another angiotensin converting enzyme inhibitor captopril has caused nagranulocytosis particularly in patients with renal impairment or ncollagenvascular disease available data are insufficient to show that ntrandolapril tablets do not have a similar risk see n warnings,",3
"n hypertension quinapril hydrochloride tablets are indicated for the treatment of hypertension it may be used alone or in combination with thiazide diuretics in using quinapril hydrochloride tablets consideration should be given to the fact that another angiotensinconverting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagen vascular disease available data are insufficient to show that quinapril hydrochloride tablets do not have a similar risk see warnings n angioedema in black patients black patients receiving ace inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to nonblacks it should also be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks none,",3
"chlorothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapychlorothiazide has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome acute glomerulonephritis and chronic renal failurechlorothiazide is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertensionroutine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemiaedema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy thiazides are indicated in pregnancy when edema is due to pathologic causes just as they are in the absence of pregnancy see precautions pregnancy,",3
"fosinopril sodium tablets are indicated for the treatment of hypertension it may be used alone or in combination with thiazide diureticsfosinopril sodium tablets are indicated in the management of heart failure as adjunctive therapy when added to conventional therapy including diuretics with or without digitalis see dosage and administrationin using fosinopril sodium consideration should be given to the fact that another angiotensin converting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagenvascular disease available data are insufficient to show that fosinopril sodium does not have a similar risk see warningsin considering use of fosinopril sodium it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in non blacks in addition ace inhibitors for which adequate data are available cause a higher rate of angioedema in black than in nonblack patients see warnings head and neck angioedema and intestinal angioedema,",3
"methyclothiazide tablets are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertensionmethyclothiazide tablets are indicated as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapymethyclothiazide tablets have also been found useful in edema due to various forms of renal dysfunction such as the nephrotic syndrome acute glomerulonephritis and chronic renal failurethe routine use of diuretics in an otherwise healthy pregnant woman is inappropriate and exposes mother and fetus to unnecessary hazard diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of developed toxemiaedema during pregnancy may arise from pathological causes or from the physiological and mechanical consequences of pregnancy thiazides are indicated in pregnancy when edema is due to pathological causes just as they are in the absence of pregnancy see precautions pregnancy,",3
"n 11 supraventricular tachycardia or noncompensatory sinus tachycardia esmolol hydrochloride injection is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative postoperative or other emergent circumstances where short term control of ventricular rate with a shortacting agent is desirable esmolol hydrochloride injection is also indicated in noncompensatory sinus tachycardia where in the physician? judgment the rapid heart rate requires specific intervention esmolol hydrochloride injection is intended for shortterm use n 12 intraoperative and postoperative tachycardia and hypertension esmolol hydrochloride injection is indicated for the shortterm treatment of tachycardia and hypertension that occur during induction and tracheal intubation during surgery on emergence from anesthesia and in the postoperative period when in the physician? judgment such specific intervention is considered indicated none none esmolol hydrochloride injection is a beta adrenergic blocker indicated for the shortterm treatment of n control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardiaxa011 control of perioperative tachycardia and hypertensionxa012,",3
"carvedilol is an alphabetaadrenergic blocking agent indicated for the treatment ofxa0 n mild to severe chronic heart failure n n n 11 left ventricular dysfunction following myocardial infarction in clinically stable patients n n n 12 hypertension n n n 13 carvedilol tablets are indicated for the treatment of mildtosevere chronic heart failure of ischemic or cardiomyopathic origin usually in addition to diuretics ace inhibitors and digitalis to increase survival and also to reduce the risk of hospitalization n n n seexa0 n drug interactions 74 and n clinical studies 141 none carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40 with or without symptomatic heart failure n n n see n n n clinical studies 142 none carvedilol tablets are indicated for the management of essential hypertension n n n see n n n clinical studies 143 144 see n n n drug interactions 72,",3
"stable coronary artery diseaseperindopril erbumine tablets are indicated in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease such as antiplatelet antihypertensive or lipidlowering therapy hypertension perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension perindopril erbumine tablets may be used alone or given with other classes of antihypertensives especially thiazide diuretics when using perindopril erbumine tablets consideration should be given to the fact that another angiotensin converting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagen vascular disease available data are insufficient to determine whether perindopril erbumine tablets has a similar potential see warningsin considering use of perindopril erbumine tablets it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks in addition it should be noted that black patients receiving ace inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to nonblacks see warnings head and neck angioedema,",3
"ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease stroke peripheral vascular disease or diabetes that is accompanied by at least one other cardiovascular risk factor hypertension elevated total cholesterol levels low hdl levels cigarette smoking or documented microalbuminuria to reduce the risk of myocardial infarction stroke or death from cardiovascular causes ramipril capsules can be used in addition to other needed treatment such as antihypertensive antiplatelet or lipidlowering therapy ramipril capsules are indicated for the treatment of hypertension it may be used alone or in combination with thiazide diuretics in using ramipril capsules consideration should be given to the fact that another angiotensin converting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagenvascular disease available data are insufficient to show that ramipril capsules do not have a similar risk see warningsin considering use of ramipril capsules it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks in addition ace inhibitors for which adequate data are available cause a higher rate of angioedema in black than in nonblack patients see warnings angioedema,",3
"indapamide tablets are indicated for the treatment of hypertension alone or in combination with other antihypertensive drugsindapamide tablets are also indicated for the treatment of salt and fluid retention associated with congestive heart failurethe routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard see below precautionsdiuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of developed toxemiaedema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy indapamide is indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy however see below dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose use of diuretics to lower intravascular volume in this case is illogical and unnecessary there is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother in the absence of cardiovascular disease but which is associated with edema including generalized edema in the majority of pregnant women if this edema produces discomfort increased recumbency will often provide relief in rare instances this edema may cause extreme discomfort which is not relieved by rest in these cases a short course of diuretics may provide relief and may be appropriate precautions,",3
"none enalapril maleate is indicated for the treatment of hypertension none enalapril maleate is effective alone or in combination with other antihypertensive agents especially thiazidetype diuretics the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive enalapril maleate is indicated for the treatment of symptomatic congestive heart failure usually in combination with diuretics and digitalis in these patients enalapril maleate improves symptoms increases survival and decreases the frequency of hospitalization see clinical pharmacology n heart failure mortality trials for details and limitations of survival trials in clinically stable asymptomatic patients with left ventricular dysfunction ejection fraction 35 percent enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure see clinical pharmacology n heart failure mortality trials for details and limitations of survival trials none none in using enalapril maleate consideration should be given to the fact that another angiotensin converting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagen vascular disease and that available data are insufficient to show that enalapril maleate does not have a similar risk see warnings none none in considering use of enalapril maleate it should be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks in addition it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks see warnings n head and neck angioedema,",3
"hydrochlorothiazide tablets are indicated as adjunctive therapy in edema associated with congestive heart failure hepatic cirrhosis and corticosteroid and estrogen therapy hydrochlorothiazide tablets have also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome acute glomerulonephritis and chronic renal failurehydrochlorothiazide tablets are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertensionuse in pregnancyroutine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemiaedema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy thiazides are indicated in pregnancy when edema is due to pathologic causes just as they are in the absence of pregnancy see precautions pregnancy dependent edema in pregnancy resulting from restriction of venous return by the gravid uterus is properly treated through elevation of the lower extremities and use of support stockings use of diuretics to lower intravascular volume in this instance is illogical and unnecessary during normal pregnancy there is hypervolemia which is not harmful to the fetus or the mother in the absence of cardiovascular disease however it may be associated with edema rarely generalized edema if such edema causes discomfort increased recumbency will often provide relief rarely this edema may cause extreme discomfort which is not relieved by rest in these instances a short course of diuretic therapy may provide relief and be appropriate,",3
"innopran xlcontrol of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than one drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education program? joint national committee on prevention detection evaluation and treatment of high blood pressure jncnumerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularlyelevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mmhg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension for example patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goalsome antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects eg on angina heart failure or diabetic kidney disease these considerations may guide selection of therapyinnopran xl is a beta adrenergic blocker indicated for the treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions 1limitation of use innopran xl is not indicated for the treatment of hypertensive emergencies 1,",3
"felodipine extendedrelease tablets usp are indicated for the treatment of hypertension to lower blood pressure lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including felodipinecontrol of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than 1 drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education program?  joint national committee on prevention detection evaluation and treatment of high blood pressure jncnumerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularlyelevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mmhg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension for example patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goalsome antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects eg on angina heart failure or diabetic kidney disease these considerations may guide selection of therapyfelodipine extendedrelease tablets usp may be administered with other antihypertensive agents,",3
"prazosin hydrochloride capsules usp is indicated for the treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug none control of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than one drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education programs joint national committee on prevention detection evaluation and treatment of high blood pressure jnc none numerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly none elevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mmhg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension for example patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal none some antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects eg on angina heart failure or diabetic kidney disease these considerations may guide selection of therapy none prazosin hydrochloride capsules usp can be used alone or in combination with other antihypertensive drugs such as diuretics or betaadrenergic blocking agents,",3
"nadolol tablets usp are indicated for the longterm management of patients with angina pectorisnadolol tablets usp are indicated for the treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs there are no controlled trials demonstrating risk reduction with nadolol tablets uspcontrol of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than one drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education programs joint national committee on prevention detection evaluation and treatment of high blood pressure jncnumerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularlyelevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mmhg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension for example patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goalsome antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects eg on angina heart failure or diabetic kidney disease these considerations may guide selection of therapynadolol tablets usp may be used alone or in combination with other antihypertensive agents especially thiazidetype diuretics,",3
"for the management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension,",3
"fenoldopam injection is a dopaminergic agonist indicated 11 12fenoldopam is indicated for inhospital shortterm up to 48 hours management of severe hypertension when rapid but quickly reversible emergency reduction of blood pressure is clinically indicated including malignant hypertension with deteriorating endorgan function transition to oral therapy with another agent can begin at any time after blood pressure is stable during fenoldopam infusionfenoldopam is indicated for inhospital shortterm up to 4 hours reduction in blood pressure see????clinical pharmacology 122,",3
"diphenhydramine hydrochloride in the injectable form is effective in adults and pedixadatric patients other than premature infants and neonates for the following conditions when diphenhydramine hydrochloride in the oral form is impractical n n antihistaminic n n none for amelioration of allergic reactions to bloodxa0 or plasma in anaphylaxis as an adjunct toxa0 epinephrine and other standard measures after the acute symptoms have been controlled and for xa0other xa0uncomplicated allergic conditionsxa0 of the immediate type when oral therapy is impossible or contraindicated n n motion sickness for active treatment of motion sickness n n antiparkinsonism for use in parkinsonism when oral therapy is impossible or contraindicated as followsxa0 parkinsonism in the elderly who are unable to tolerate more potent agents mild xa0cases ofxa0 parkinsonism in other age groups and in otherxa0 cases of parkinsonism in combination withxa0 centrally acting anticholinergic agents none,",3
"olsalazine is indicated for the maintenance of remission of ulcerative colitis in patients who are intolerant of sulfasalazine,",3
"mesalamine delayedrelease capsulesxa0is an aminosalicylate indicated for n treatment of mildly to moderately active ulcerative colitis in patientsxa05 years of age and older 11 none maintenance of remission of ulcerative colitis in adults 12 mesalamine delayedrelease capsulesxa0is indicated for the treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older mesalamine delayedrelease capsulesxa0is indicated for the maintenance of remission of ulcerative colitis in adults,",3
"balsalazide disodium capsules are indicated for the treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older safety and effectiveness of balsalazide beyond 8 weeks in children ages 5 to 17 years and 12 weeks in adults have not been established balsalazide is a locally acting aminosalicylate indicated for the treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older 1safety and effectiveness of balsalazide beyond 8 weeks in children ages 5 to 17 years and 12 weeks in adults have not been established 1,",3
"sulfasalazine delayed release tablets are indicated a b c d1sulfasalazine delayed release tablets are particularly indicated in patients with ulcerative colitis who cannot take uncoated sulfasalazine tablets because of gastrointestinal intolerance and in whom there is evidence that this intolerance is not primarily the result of high blood levels of sulfapyridine and its metabolites eg patients experiencing nausea and vomiting with the first few doses of the drug or patients in whom a reduction in dosage does not alleviate the adverse gastrointestinal effectsin patients with rheumatoid arthritis or juvenile rheumatoid arthritis rest and physiotherapy as indicated should be continued unlike antiinflammatory drugs sulfasalazine delayed release tablets do not produce an immediate response concurrent treatment with analgesics andor nonsteroidal antiinflammatory drugs is recommended at least until the effect of sulfasalazine delayed release tablets is apparent,",3
"simponi is a tumor necrosis factor tnf blocker indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis ra in combination with methotrexate 11active psoriatic arthritis psa alone or in combination with methotrexate 12active ankylosing spondylitis as 13moderate to severe ulcerative colitis uc with an inadequate response or intolerant to prior treatment or requiring continuous steroid therapy 14 inducing and maintaining clinical responseimproving endoscopic appearance of the mucosa during inductioninducing clinical remissionachieving and sustaining clinical remission in induction responderssimponi in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritissimponi alone or in combination with methotrexate is indicated for the treatment of adult patients with active psoriatic arthritissimponi is indicated for the treatment of adult patients with active ankylosing spondylitis simponi is indicated in adult patients with moderately to severely active ulcerative colitis who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral aminosalicylates oral corticosteroids azathioprine or 6mercaptopurine for inducing and maintaining clinical response improving endoscopic appearance of the mucosa during induction inducing clinical remission achieving and sustaining clinical remission in induction responders see clinical studies 144,",3
"entyvio is an integrin receptor antagonist indicated for adult ulcerative colitis uc 11 adult patients with moderately to severely active uc who have had an inadequate response with lost response to or were intolerant to a tumor necrosis factor tnf blocker or immunomodulator or had an inadequate response with were intolerant to or demonstrated dependence on corticosteroids inducing and maintaining clinical responseinducing and maintaining clinical remissionimproving endoscopic appearance of the mucosaachieving corticosteroidfree remission adult crohns disease cd 12 adult patients with moderately to severely active cd who have had an inadequate response with lost response to or were intolerant to a tnf blocker or immunomodulator or had an inadequate response with were intolerant to or demonstrated dependence on corticosteroids achieving clinical responseachieving clinical remissionachieving corticosteroidfree remissionentyvio vedolizumab is indicated for inducing and maintaining clinical responseinducing and maintaining clinical remissionimproving the endoscopic appearance of the mucosa andachieving corticosteroidfree remissionin adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with lost response to or were intolerant to a tumor necrosis factor tnf blocker or immunomodulator or had an inadequate response with were intolerant to or demonstrated dependence on corticosteroidsentyvio vedolizumab is indicated for achieving clinical response achieving clinical remission andachieving corticosteroidfree remissionin adult patients with moderately to severely active crohns disease who have had an inadequate response with lost response to or were intolerant to a tumor necrosis factor tnf blocker or immunomodulator or had an inadequate response with were intolerant to or demonstrated dependence on corticosteroids,",3
"imraldi is a tumor necrosis factor tnf blocker indicated for treatment of rheumatoid arthritis ra 11 juvenile idiopathic arthritis jia 12 psoriatic arthritis psa 13 ankylosing spondylitis as 14 adult crohns disease cd 15 ulcerative colitis uc 16 plaque psoriasis ps 17imraldi is indicated for reducing signs and symptoms inducing major clinical response inhibiting the progression of structural damage and improving physical function in adult patients with moderately to severely active rheumatoid arthritis imraldi can be used alone or in combination with methotrexate or other nonbiologic diseasemodifying antirheumatic drugs dmardsimraldi is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients from 4 to 17 years of age and lbs imraldi can be used alone or in combination with methotrexateimraldi is indicated for reducing signs and symptoms inhibiting the progression of structural damage and improving physical function in adult patients with active psoriatic arthritis imraldi can be used alone or in combination with nonbiologic dmardsimraldi is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitisimraldi is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohns disease who have had an inadequate response to conventional therapy imraldi is indicated for reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximabimraldi is indicated for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to immunosuppressants such as corticosteroids azathioprine or 6mercaptopurine 6mp the effectiveness of adalimumab has not been established in patients who have lost response to or were intolerant to tnf blockers see clinical studies 147imraldi is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy and when other systemic therapies are medically less appropriate imraldi should only be administered to patients who will be closely monitored and have regular followup visits with a physician see boxed warning5,",3
"loteprednol etabonate is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva cornea and anterior segment of the globe such as allergic conjunctivitis acne rosacea superficial punctate keratitis herpes zoster keratitis iritis cyclitis selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation loteprednol etabonate is less effective than prednisolone acetate 1 in two 28day controlled clinical studies in acute anterior uveitis where 72 of patients treated with loteprednol etabonate experienced resolution of anterior chamber cells compared to 87 of patients treated with prednisolone acetate 1 the incidence of patients with clinically significant increases in iop ? 10 mmhg was 1 with loteprednol etabonate and 6 with prednisolone acetate 1 loteprednol etabonate should not be used in patients who require a more potent corticosteroid for this indicationloteprednol etabonate is also indicated for the treatment of postoperative inflammation following ocular surgery,",3
"hydrocortisone tabletsxa0are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancern none none none as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis posttraumatic osteoarthritis synovitis of osteoarthritis epicondylitisn none none none none none none none none during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditisn none none pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitisn none none none none none none control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactionsn none none none none none severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmian none none none none none none none none none symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitisn none none none none idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemian none none none none for palliative management of leukemias and lymphomas in adults acute leukemia of childhoodn none to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in ulcerative colitis regional enteritisn none acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement,",3
"metastatic prostate cancernilutamide tablets are indicated for use in combination with surgical castration for the treatment of metastatic prostate cancer stage d2for maximum benefit treatment with nilutamide tablets must begin on the same day as or on the day after surgical castration,",3
"motegrity is indicated for the treatment of chronic idiopathic constipation cic in adultsmotegrity is a serotonin4 5ht411,",3
"zafirlukast tablets are indicated for the prophylaxis and chronic treatment of asthma in adults and children 5 years of age and older,",3
"metaproterenol sulfate tablets are indicated as a bronchodilator for bronchial asthma and for reversible bronchospasm which may occur in association with bronchitis and emphysema,",3
"cromolyn sodium inhalation solution usp is a prophylactic agent indicated in the management of patients with bronchial asthmain patients whose symptoms are sufficiently frequent to require a continuous program of medication cromolyn sodium inhalation solution usp is given by inhalation on a regular daily basis see dosage and administrationin patients who develop acute bronchoconstriction in response to exposure to exercise toluene diisocyanate environmental pollutants etc cromolyn sodium should be given shortly before exposure to the precipitating factor see dosage and administration,",3
"spiriva respimat is an anticholinergicnindicated for n the longterm oncedaily maintenance treatment of bronchospasmnassociated with chronic obstructive pulmonary disease copd andnfor reducing copd exacerbations 11 the longterm oncedaily maintenance treatment of asthmanin patients 6 years of age and older 12 limitation of use n not indicated for relief of acute bronchospasm 11 12 51 spiriva respimat tiotropium bromide isnindicated for the longterm oncedaily maintenance treatment ofnbronchospasm associated with chronic obstructive pulmonary diseasencopd including chronic bronchitis and emphysema spiriva respimatnis indicated to reduce exacerbations in copd patients important limitation of use none spiriva respimat is a bronchodilator indicated for the longtermnoncedaily maintenance treatment of asthma in patients 6 years ofnage and older importantnlimitation of use none,",3
"none montelukast sodium tablets are a leukotriene receptor antagonist indicated for n prophylaxis and chronic treatment of asthma in patients 2 years of age and older 11 acute prevention of exerciseinduced bronchoconstriction eib in patients 15 years of age and older 12 relief of symptoms of allergic rhinitis ar seasonal allergic rhinitis sar in patients 2 years of age and older and perennial allergic rhinitis par in patients 2 years of age and older 13 montelukast sodium is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 2 years of age and older montelukast sodium is indicated for prevention of exerciseinduced bronchoconstriction eib in patients 15 years of age and older n pediatric use information for patients ages 6 to 14 years of age for acute prevention of exerciseinduced bronchoconstriction eib is approved for merck sharp dohme corp? s montelukast tablet products however due to merck sharp dohme corp marketing exclusivity rights this drug product is not labeled with that pediatric information montelukast sodium is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 2 years of age and older,",3
"xolair is an antiige antibody indicated for moderate to severe persistent asthma in patients 6 years of age and older with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids 11 chronic idiopathic urticaria in adults and adolescents 12 years of age and older who remain symptomatic despite h1 antihistamine treatment 12limitations of use not indicated for other allergic conditions or other forms of urticaria 1112 not indicated for acute bronchospasm or status asthmaticus 1153xolair is indicated for patients 6 years of age and older with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroidsxolair has been shown to decrease the incidence of asthma exacerbations in these patients limitations of use xolair is not indicated for the relief of acute bronchospasm or status asthmaticusxolair is not indicated for treatment of other allergic conditionsxolair is indicated for the treatment of adults and adolescents 12 years of age and older with chronic idiopathic urticaria who remain symptomatic despite h1 antihistamine treatment limitation of usexolair is not indicated for treatment of other forms of urticaria,",3
"when oral therapy is not feasible the intramuscular usecontrol of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis serum sickness transfusion reactionsbullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus severe erythema multiforme stevensjohnson syndromecongenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditishydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importanceto tide the patient over a critical period of the disease in regional enteritis and ulcerative colitisacquired autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia selected cases of secondary thrombocytopeniatrichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapyfor palliative management of leukemias and lymphomasacute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor or craniotomysympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroidsto induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosusberylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosisas adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosusthe intraarticular or soft tissue administrationthe intralesional administrationbetamethasone sodium phosphate and betamethasone acetate injectable suspension may also be useful in cystic tumors of an aponeurosis or tendon ganglia,",3
"hydrocortisone tabletsxa0are indicated in the following conditions primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia non suppurative thyroiditis hypercalcemia associated with cancern none none none as adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis posttraumatic osteoarthritis synovitis of osteoarthritis epicondylitisn none none none none none none none none during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus systemic dermatomyositis polymyositis acute rheumatic carditisn none none pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevensjohnson syndrome exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrheic dermatitisn none none none none none none control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment seasonal or perennial allergic rhinitis serum sickness bronchial asthma contact dermatitis atopic dermatitis drug hypersensitivity reactionsn none none none none none severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as allergic conjunctivitis keratitis allergic corneal marginal ulcers herpes zoster ophthalmicus iritis and iridocyclitis chorioretinitis anterior segment inflammation diffuse posterior uveitis and choroiditis optic neuritis sympathetic ophthalmian none none none none none none none none none symptomatic sarcoidosis loefflers syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitisn none none none none idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired autoimmune hemolytic anemia erythroblastopenia rbc anemia congenital erythroid hypoplastic anemian none none none none for palliative management of leukemias and lymphomas in adults acute leukemia of childhoodn none to induce a diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus to tide the patient over a critical period of the disease in ulcerative colitis regional enteritisn none acute exacerbations of multiple sclerosis tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement,",3
"azelaic acid gel 15 is indicated for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea although some reduction of erythema which was present in patients with papules and pustules of rosacea occurred in clinical studies efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated azelaic acid gel 15 is indicated for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated 1,",3
"loteprednol etabonate is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva cornea and anterior segment of the globe such as allergic conjunctivitis acne rosacea superficial punctate keratitis herpes zoster keratitis iritis cyclitis selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation loteprednol etabonate is less effective than prednisolone acetate 1 in two 28day controlled clinical studies in acute anterior uveitis where 72 of patients treated with loteprednol etabonate experienced resolution of anterior chamber cells compared to 87 of patients treated with prednisolone acetate 1 the incidence of patients with clinically significant increases in iop 10 mmhg was 1 with loteprednol etabonate and 6 with prednisolone acetate 1 loteprednol etabonate should not be used in patients who require a more potent corticosteroid for this indicationloteprednol etabonate is also indicated for the treatment of postoperative inflammation following ocular surgery,",3
"miglitol tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,",3
"tolazamide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,",3
"onglyza is a dipeptidyl peptidase4 dpp4 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings 11 14 n none n n 12 n 12 51 onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings see n clinical studies 14 onglyza should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis as it would not be effective in these settings onglyza has not been studied in patients with a history of pancreatitis it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using onglyza see n warnings and precautions 51,",3
"tradjenta is a dipeptidyl peptidase4 dpp4ninhibitor indicated as an adjunct to diet and exercise to improvenglycemic control in adults with type 2 diabetes mellitus 11 none important limitations of use n should not be used in patients with type 1 diabetes or fornthe treatment of diabetic ketoacidosis 12 has not been studied in patients with a history of pancreatitis 12 tradjenta is indicated as an adjunct to diet and exercisento improve glycemic control in adults with type 2 diabetes mellitus n see clinical studies 141 tradjenta shouldnnot be used in patients with type 1 diabetes or for the treatmentnof diabetic ketoacidosis as it would not be effective in these settings tradjenta has not been studied in patientsnwith a history of pancreatitis it is unknown whether patients withna history of pancreatitis are at an increased risk for the developmentnof pancreatitis while using tradjenta see warnings and precautions 51,",3
"n monotherapy and combination therapy n pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings see clinical studies 14 n none n important limitations of use n pioglitazone tablets exert their antihyperglycemic effect only in the presence of endogenous insulin pioglitazone tablets should not be used to treat type 1 diabetes or diabetic ketoacidosis as it would not be effective in these settings n use caution in patients with liver disease see warnings and precautions 53 pioglitazone tablets are a thiazolidinedione and an agonist for peroxisome proliferatoractivated receptor ppar gamma indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings 1 14 none none n important limitations of use n not for treatment of type 1 diabetes or diabetic ketoacidosis 1,",3
"n none dicyclomine hydrochloride injection is an antispasmodic and anticholinergic antimuscarinic agent indicated for the treatment of functional bowelirritable bowel syndrome n n n 1 dicyclomine hydrochloride injection is indicated for the treatment of patients with functional bowelirritable bowel syndrome,",3
"linzess is indicated in adults for the treatment of n irritable bowel syndrome with constipation ibsc none chronic idiopathic constipation cic linzess is a guanylate cyclasec agonist indicated in adults for treatment of n irritable bowel syndrome with constipation ibsc 1 none chronic idiopathic constipation cic 1,",3
"hyoscyamine sulfate is effective as adjunctive therapy in the treatment of peptic ulcer it can also be used to control gastric secretion visceral spasm and hypermotility in spastic colitis spastic bladder cystitis pylorospasm and associated abdominal cramps may be used in functional intestinal disorders to reduce symptoms such as those seen in mild dysenteries diverticulitis and acute enterocolitis for use as adjunctive therapy in the treatment of irritable bowel syndrome irritable colon spastic colon mucous colitis and functional gastrointestinal disorders also used as adjunctive therapy in the treatment of neurogenic bladder and neurogenic bowel disturbances including the splenic flexure syndrome and neurogenic colon also used in the treatment of infant colic elixir and drops hyoscyamine sulfate is indicated along with morphine or other narcotics in symptomatic relief of biliary and renal colic as a drying agent in the relief of symptoms of acute rhinitis in the therapy of parkinsonism to reduce rigidity and tremors and to control associated sialorrhea and hyperhidrosis may be used in the therapy of poisoning by anticholinesterase agents,",3
"marqibo is a vinca alkaloid indicated for the treatment of adult patients with philadelphia chromosomenegative ph acute lymphoblastic leukemia all in second or greater relapse or whose disease has progressed following two or more antileukemia therapies this indication is based on overall response rate clinical benefit such as improvement in overall survival has not been verified 11marqibo,",3
"cytarabine injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia of adults and pediatric patients it has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia intrathecal administration of cytarabine injection preservative free preparations only is indicated in the prophylaxis and treatment of meningeal leukemia,",3
"carteolol hydrochloride ophthalmic solution 1 has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic openangle glaucoma and intraocular hypertension it may be used alone or in combination with other intraocular pressure lowering medications,",3
"methazolamide tablets usp is indicated in the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit such as chronic openangle glaucoma secondary glaucoma and preoperatively in acute angleclosure glaucoma where lowering the intraocular pressure is desired before surgery,",3
"pilocarpine hydrochloride can be used in the medical management of glaucoma especially openangle glaucoma in those cases in which the intraocular pressure can be controlled adequately by the topical administration of pilocarpine in acute closedangle glaucoma pilocarpine hydrochloride may be used alone or in combination with other cholinergic agents or carbonic anhydrase inhibitors to relieve tension prior to emergency surgerypatients may be maintained on pilocarpine hydrochloride as long as intraocular pressure is controlled and there is no deterioration in the visual fields the choice of concentration should be determined by the severity of the condition and the response of the patient pilocarpine hydrochloride is also indicated to counter the effects of cycloplegics and mydriatics following surgery or ophthalmoscopic examination,",3
"for adjunctive treatment of edema due to congestive heart failure druginduced edema centrencephalic epilepsies petit mal unlocalized seizures chronic simple openangle glaucoma secondary glaucoma and preoperatively in acute angleclosure glaucoma where delay of surgery is desired in order to lower intraocular pressure acetazolamide tablets are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent,",3
"levobunolol hcl ophthalmic solution has been shown to be effective in lowering intraocular pressure and may be used????in patients with chronic openangle glaucoma or ocular hypertension,",3
"latanoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with openangle glaucoma or ocular hypertensionlatanoprost ophthalmic solution is a prostaglandin f2 analogue indicated for the reduction of elevated intraocular pressure in patients with openangle glaucoma or ocular hypertension 1,",3
"betaxolol hydrochloride ophthalmic solution has been shown to be effective in lowering intraocular pressure and is indicated in the treatment of ocular hypertension and chronic openangle glaucoma it may be used alone or in combination with other antiglaucoma drugsin clinical studies betaxolol hydrochloride ophthalmic solution was safely used to lower intraocular pressure in 47 patients with both glaucoma and reactive airway disease who were followed for a mean period of 15 months however caution should be used in treating patients with severe reactive airway disease or a history of asthma,",3
"ergocalciferol capsules usp are indicated for use in the treatment of hypoparathyroidism refractory rickets also known as vitamin d resistant rickets and familial hypophosphatemia,",3
"ergocalciferol capsules usp are indicated for use in the treatment of hypoparathyroidism refractory rickets also known as vitamin d resistant rickets and familial hypophosphatemia,",3
"neupro is a dopamine agonist indicated for the treatment of parkinsons disease 11moderatetosevere primary restless legs syndrome 12neupro is indicated for the treatment of parkinsons diseaseneupro is indicated for the treatment of moderatetosevere primary restless legs syndrome,",3
"inbrija is indicated for the intermittent treatment of off episodes in patients with parkinsons disease treated with carbidopalevodopainbrija is an aromatic amino acid indicated for the intermittent treatment of off episodes in patients with parkinsons disease treated with carbidopalevodopa 1,",3
"apokyn apomorphine hydrochloride injection is indicated for the acute intermittent treatment of hypomobility off episodes endofdose wearing off and unpredictable onoff episodes in patients with advanced parkinsons disease apokyn has been studied as an adjunct to other medications see clinical studies 14apokyn is a nonergoline dopamine agonist indicated for the acute intermittent treatment of hypomobility off episodes endofdose wearing off and unpredictable onoff episodes associated with advanced parkinsons disease 1,",3
"cyclosporine capsules usp modified are indicated for the prophylaxis of organ rejection in kidney liver and heart allogeneic transplants cyclosporine capsules usp modified have been used in combination with azathioprine and corticosteroidscyclosporine capsules usp modified are indicated for the treatment of patients with severe active rheumatoid arthritis where the disease has not adequately responded to methotrexate cyclosporine capsules usp modified can be used in combination with methotrexate in rheumatoid arthritis patients who do not respond adequately to methotrexate alonecyclosporine capsules usp modified are indicated for the treatment of adult nonimmunocompromised patients with severe ie extensive andor disabling recalcitrant plaque psoriasis who have failed to respond to at least one systemic therapy eg puva retinoids or methotrexate or in patients for whom other systemic therapies are contraindicated or cannot be toleratedwhile rebound rarely occurs most patients will experience relapse with cyclosporine capsules usp modified as with other therapies upon cessation of treatment,",3
"carefully consider the potential benefits and risks of ibuprofen oral suspension and other treatment options before deciding to use ibuprofen oral suspension use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see n warnings none n in pediatric patients ibuprofen oral suspension is indicated n for reduction of fever in patients aged 6 months up to 2 years of age for relief of mild to moderate pain in patients aged 6 months up to 2 years of age for relief of signs and symptoms of juvenile arthritis none n in adults ibuprofen oral suspension is indicated n for treatment of primary dysmenorrhea for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis none since there have been no controlled trials to demonstrate whether there is any beneficial effect or harmful interaction with the use of ibuprofen in conjunction with aspirin the combination cannot be recommended see n precautionsdrug interactions,",2
"ridaura auranofin is indicated in the management of adults with active classical or definite rheumatoid arthritis ara criteria who have had an insufficient therapeutic response to or are intolerant of an adequate trial of full doses of one or more nonsteroidal antiinflammatory drugs ridaura should be added to a comprehensive baseline program including nondrug therapiesunlike antiinflammatory drugs ridaura does not produce an immediate response therapeutic effects may be seen after three to four months of treatment although improvement has not been seen in some patients before six monthswhen cartilage and bone damage has already occurred gold cannot reverse structural damage to joints caused by previous disease the greatest potential benefit occurs in patients with active synovitis particularly in its early stagein controlled clinical trials comparing ridaura with injectable gold ridaura was associated with fewer dropouts due to adverse reactions while injectable gold was associated with fewer dropouts for inadequate or poor therapeutic effect physicians should consider these findings when deciding on the use of ridaura in patients who are candidates for chrysotherapy,",3
"enter section text here n none n treatment of schizophrenia in adults 11 alone or in combination with lithium or valproate for the shortterm ntreatment of acute manic or mixed episodes associated with bipolar i disorder in nadults 12 due to janssen pharmaceuticals corporation? marketing exclusivity rights nthis drug product is not labeled for use in pediatric patients with nschizophrenia or bipolar mania 11 12 treatment of irritability associated with autistic disorder in children and nadolescents aged 516 years 13 none n none risperidone tablets are indicated for the acute and maintenance treatment of nschizophrenia see clinical studies n141 adolescents due to janssen pharmaceuticals corporation marketing exclusivity rights nthis drug product is not labeled for use in pediatric patients with nschizophrenia pediatric use information for the treatment of pediatric patients nwith schizophrenia 13 to 17 years of age is approved for janssen npharmaceuticals corporation risperidone drug products n none risperidone tablets are indicated for the shortterm treatment of acute manic nor mixed episodes associated with bipolar i disorder in adults see clinical studies 142 due to janssen pharmaceuticals corporation marketing exclusivity rights nthis drug product is not labeled for use in pediatric patients with bipolar nmania pediatric use information for the treatment of pediatric patients with nbipolar mania 10 to 17 years of age is approved for janssen pharmaceuticals ncorporation risperidone drug products combination therapy adults the combination of risperidone with lithium or valproate is indicated for the nshortterm treatment of acute manic or mixed episodes associated with bipolar i ndisorder see clinical studies n143 n none risperidone tablets are indicated for the treatment of irritability nassociated with autistic disorder in children and adolescents aged 516 years nincluding symptoms of aggression towards others deliberate selfinjuriousness ntemper tantrums and quickly changing moods see clinical nstudies 144,",3
"ofev is indicated for the treatment of idiopathicnpulmonary fibrosis ipf ofev is a kinase inhibitor indicatednfor the treatment of idiopathic pulmonary fibrosis ipf 1 none,",3
"otezla an inhibitor of phosphodiesterase 4 pde4 is indicated for the treatment of adult patients with active psoriatic arthritis 11patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy 12otezla is indicated for the treatment of adult patients with active psoriatic arthritisotezla is indicated for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy,",3
"firazyrfirazyr is a bradykinin b2 receptor antagonist indicated for treatment of acute attacks of hereditary angioedema hae in adults 18 years of age and older 1,",3
"gynazole 1 butoconazole nitrate vaginal cream usp 2 is indicated for the local treatment of vulvovaginal candidiasis infections caused by candidaclinical studies note precautions pregnancy,",3
"terconazole vaginal cream 04 is indicated for the local treatment of vulvovaginal candidiasis moniliasis as terconazole vaginal cream 04 is effective only for vulvovaginitis caused by the genus candida the diagnosis should be confirmed by koh smears andor cultures,",3
"miconazole nitrate vaginal suppositories usp 200 mg are indicated for the local treatment of vulvovaginal candidiasis moniliasis effectiveness in pregnancy has not been established as miconazole nitrate is effective only for candidal vulvovaginitis the diagnosis should be confirmed by koh smear andor cultures other pathogens commonly associated with vulvovaginitis trichomonas haemophilus vaginalis gardnerella,",3
"temsirolimus injection is indicated for the treatment of advanced renal cell carcinomatemsirolimus injection is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma 1,",3
"inlyta is indicated for the treatment of advanced renal cell carcinoma rcc after failure of one prior systemic therapyinlyta is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy 1,",3
"yondelissee clinical studies 14yondelis is an alkylating drug indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracyclinecontaining regimen 1,",3
"idarubicin hydrochloride injection usp in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia aml in adults this includes frenchamericanbritish fab classifications m1 through m7,",3
"doxorubicin hydrochloride hcl for injection is an anthracycline topoisomerase ii inhibitor indicated n as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer 11 for the treatment of acute lymphoblastic leukemia acute myeloblastic leukemia hodgkin lymphoma nonhodgkin lymphoma metastatic breast cancer metastatic wilms tumor metastatic neuroblastoma metastatic soft tissue sarcoma metastatic bone sarcomas metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma 12 none none doxorubicin hcl for injection is indicated as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer see clinical studies 14 n none none none doxorubicin hcl for injection is indicated for the treatment of n acute lymphoblastic leukemia acute myeloblastic leukemia hodgkin lymphoma nonhodgkin lymphoma nhl metastatic breast cancer metastatic wilms tumor metastatic neuroblastoma metastatic soft tissue sarcoma metastatic bone sarcoma metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma none none,",3
"sylatron sylatron is an alpha interferon indicated for the adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy 1,",3
"dacarbazine for injection usp is indicated in the treatment of metastatic malignant melanoma in addition dacarbazine for injection usp is also indicated for hodgkins disease as a secondline therapy when used in combination with other effective agents,",3
"helps loosen phlegm mucus and thin bronchial secretions to rid the bronchial passageways of bothersome mucus drain bronchial tubes and make coughs more productive helps loosen phlegm and thin bronchial secretions in patients with stable chronic bronchitis,",2
"levobunolol hcl ophthalmic solution has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic openangle glaucoma or ocular hypertension,",3
"none bimatoprost ophthalmic solution 003 is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension bimatoprost ophthalmic solution 003 is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension,",3
"travoprost ophthalmic solution usp 0004 is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertensiontravoprost ophthalmic solution usp 0004 is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension 1,",3
"brimonidine tartrate ophthalmic solution 02 is indicated for lowering intraocular pressure iop in patients with openangle glaucoma or ocular hypertensionthe iop lowering efficacy of brimonidine tartrate ophthalmic solution diminishes over time in some patients this loss of effect appears with a variable time of onset in each patient and should be closely monitoredbrimonidine tartrate ophthalmic solution 02 is an alpha adrenergic agonist indicated for lowering intraocular pressure iop in patients with openangle glaucoma or ocular hypertension 1,",3
"tolcapone tablets usp is indicated as an adjunct to levodopa and carbidopa for the treatment of the signs and symptoms of idiopathic parkinsons disease because of the risk of potentially fatal acute fulminant liver failure tolcapone tablets usp should ordinarily be used in patients with parkinsons disease on ldopacarbidopa who are experiencing symptom fluctuations and are not responding satisfactorily to or are not appropriate candidates for other adjunctive therapies because of the risk of liver injury and because tolcapone tablets usp when it is effective provides an observable symptomatic benefit the patient who fails to show substantial clinical benefit within 3 weeks of initiation of treatment should be withdrawn from tolcapone tablets uspthe effectiveness of tolcapone tablets usp was demonstrated in randomized controlled trials in patients receiving concomitant levodopa therapy with carbidopa or another aromatic amino acid decarboxylase inhibitor who experienced end of dose wearingoff phenomena as well as in patients who did not experience such phenomena see clinical pharmacologyclinical studies,",2
"nan,",3
"carefully consider the potential benefits and risks of salsalate tablets usp and other treatment options before deciding to use salsalate tablets usp use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see salsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis osteoarthritis and related rheumatic disorder warnings,",2
"carefully consider the potential benefits and risks of diflunisal tablets and other treatment options before deciding to use diflunisal tablets use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warningsdiflunisal tablets are indicated for acute or longterm use for symptomatic treatment of the following1 mild to moderate pain2 osteoarthritis3 rheumatoid arthritis,",2
"none carefully consider the potential benefits and risks of nflurbiprofen tablets and other treatment options before deciding to use nflurbiprofen tablets use the lowest effective dose for the shortest duration nconsistent with individual patient treatment goals see warnings flurbiprofen tablets are indicated n for relief of the signs and symptoms of rheumatoid arthritis n for relief of the signs and symptoms of osteoarthritis,",2
"carefully consider the potential benefits and risks of nabumetone tablets usp and other treatment options before deciding to use nabumetone tablets usp use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warnings nabumetone tablets usp are indicated for relief of the signs and symptoms of rheumatoid arthritis for relief of the signs and symptoms of osteoarthritis,",2
"piroxicam capsule is indicated none n for relief of the signs and symptoms of osteoarthritis for relief of the signs and symptoms of rheumatoid arthritis piroxicam capsuleis a nonste roidal anti infla mmato ry d rug indicated for n relief of the signs and sy mpt o ms of osteoarthritis oa n n n 1 relief of the signs and sy mpto ms of rheu m atoid arthritis ra n n n 1,",2
"carefully consider the potential benefits and risks of etodolac extendedrelease tablets usp and other treatment options before deciding to use etodolac extendedrelease tablets usp use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warningsetodolac extendedrelease tablets usp are indicated for relief of signs and symptoms of juvenile arthritis for relief of the signs and symptoms of rheumatoid arthritis for relief of the signs and symptoms of osteoarthritis,",2
"oxaprozin tablets are indicated n for relief of the signs and symptoms of osteoarthritis for relief of the signs and symptoms of rheumatoid arthritis for relief of the signs and symptoms of juvenile rheumatoid arthritis none oxaprozin is a nonsteroidal antiinflammatory drug indicated for n relief of signs and symptoms of osteoarthritis oa 1 relief of signs and symptoms of rheumatoid arthritis ra 1 relief of signs and symptoms of juvenile rheumatoid arthritis jra 1 none,",2
"fenoprofen calcium usp is indicated for n relief of mild to moderate pain in adults relief of the signs and symptoms of rheumatoid arthrites relief of the signs and symptoms of osteoarthritis none fenoprofen calcium usp is a nonsteroidal antiinflammatory drug indicated for none n relief of mild to moderate pain in adults n n n n 1 relief of the signs and symptoms of rheumatoid arthritis n n n n 1 relief of the signs and symptoms of osteoarthritis n n n n 1,",2
"carefully consider the potential benefits and risks of ketoprofen immediaterelease capsules and ketoprofen extendedrelease capsules before deciding to use ketoprofen immediaterelease capsules and ketoprofen extendedrelease capsules use of the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warningsketoprofen immediaterelease capsules and ketoprofen extendedrelease capsules are indicated for the management of the signs and symptoms of rheumatoid arthritis and osteoarthritisketoprofen extendedrelease capsules are not recommended for treatment of acute pain because of its extendedrelease characteristics see clinical pharmacology pharmacokineticsketoprofen immediaterelease capsules are indicated for the management of pain ketoprofen immediaterelease capsules are also indicated for treatment of primary dysmenorrhea,",2
"carefully consider the potential benefits and risks of tolmetin sodium capsules usp and other treatment options before deciding to use tolmetin sodium capsules use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warningstolmetin sodium capsules are indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis tolmetin sodium capsules are indicated in the treatment of acute flares and the longterm management of the chronic diseasetolmetin sodium capsules are also indicated for treatment of juvenile rheumatoid arthritis the safety and effectiveness of tolmetin sodium capsules have not been established in pediatric patients under 2 years of age see precautions pediatric usedosage and administration,",2
"carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see n n n n warnings sulindac tabletsxa0uspxa0are indicated for acute orxa0longterm use in the relief of signs and symptoms of the following n n osteoarthritis n rheumatoid arthritis n ankylosing spondylitis n acute painful shoulder acute subacromial bursitissupraspinatus tendinitis n acute gouty arthritis n none n n xa0 the safety and effectiveness of sulindac have not been established in rheumatoid arthritis patients who are designated in the american rheumatism association classification as functional class iv incapacitated largely or wholly bedridden or confined to wheelchair little or no selfcare,",2
"carefully consider the potential benefits and risks of naprosyn ecnaprosyn anaprox anaprox ds or naprosyn suspension and other treatment options before deciding to use naprosyn ecnaprosyn anaprox anaprox ds or naprosyn suspension use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see n n n n warnings naproxen as naprosyn ecnaprosyn anaprox anaprox ds or naprosyn suspension is indicated n for the relief of the signs and symptoms of rheumatoid arthritisn n n none for the relief of the signs and symptoms of osteoarthritisn n n none for the relief of the signs and symptoms of ankylosing spondylitisn n n none for the relief of the signs and symptoms of juvenile arthritis naproxen as naprosyn suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patients weight naproxen as naprosyn anaprox anaprox ds and naprosyn suspension is also indicated n for relief of the signs and symptoms of tendonitisn n n none for relief of the signs and symptoms of bursitisn n n none for relief of the signs and symptoms of acute goutn n n none for the management of painn n n none for the management of primary dysmenorrhea ecnaprosyn is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxencontaining products see n n n n clinical pharmacology n dosage and administration,",2
"carefully consider the potential benefits and risks of salsalate tablets usp and other treatment options before deciding to use salsalate tablets usp use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see salsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis osteoarthritis and related rheumatic disorder warnings,",2
"carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see n n n n warnings sulindac tabletsxa0uspxa0are indicated for acute orxa0longterm use in the relief of signs and symptoms of the following n n osteoarthritis n rheumatoid arthritis n ankylosing spondylitis n acute painful shoulder acute subacromial bursitissupraspinatus tendinitis n acute gouty arthritis n none n n xa0 the safety and effectiveness of sulindac have not been established in rheumatoid arthritis patients who are designated in the american rheumatism association classification as functional class iv incapacitated largely or wholly bedridden or confined to wheelchair little or no selfcare,",2
"carefully consider the potential benefits and risks of naprosyn ecnaprosyn anaprox anaprox ds or naprosyn suspension and other treatment options before deciding to use naprosyn ecnaprosyn anaprox anaprox ds or naprosyn suspension use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see n n n n warnings naproxen as naprosyn ecnaprosyn anaprox anaprox ds or naprosyn suspension is indicated n for the relief of the signs and symptoms of rheumatoid arthritisn n n none for the relief of the signs and symptoms of osteoarthritisn n n none for the relief of the signs and symptoms of ankylosing spondylitisn n n none for the relief of the signs and symptoms of juvenile arthritis naproxen as naprosyn suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patients weight naproxen as naprosyn anaprox anaprox ds and naprosyn suspension is also indicated n for relief of the signs and symptoms of tendonitisn n n none for relief of the signs and symptoms of bursitisn n n none for relief of the signs and symptoms of acute goutn n n none for the management of painn n n none for the management of primary dysmenorrhea ecnaprosyn is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxencontaining products see n n n n clinical pharmacology n dosage and administration,",2
"neupogen is a leukocyte growth factor indicated to n decrease the incidence of infection as manifested by febrile neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever 11 none reduce the time to neutrophil recovery and the duration of fever following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia aml 12 none reduce the duration of neutropenia and neutropeniarelated clinical sequelae febrile neutropenia in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation bmt 13 none mobilizexa0autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis 14 none reduce the incidence and duration of sequelae of severe neutropenia eg fever infections oropharyngeal ulcers in symptomatic patients with congenital neutropenia cyclic neutropenia or idiopathic neutropenia 15 none increase survival in patients acutely exposed to myelosuppressive doses of radiation hematopoietic syndrome of acute radiation syndrome 16 neupogen is indicated to decrease the incidence of infection as manifested by febrile neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever see clinical studies n 141 neupogen is indicated for reducing the time to neutrophil recovery and the duration of fever following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia aml see clinical studies n 142 neupogen is indicated to reduce the duration of neutropenia and neutropeniarelated clinical sequelae eg febrile neutropenia in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation see clinical studies n 143 neupogen is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis see clinical studies n 144 neupogen is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia eg feverinfections oropharyngeal ulcers in symptomatic patients with congenital neutropenia cyclic neutropenia or idiopathic neutropenia see clinical studies n 145 neupogenxa0is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation see clinical studies n 146 xa0,",3
"fabrazymefabrazyme is indicated for use in patients with fabry disease fabrazyme reduces globotriaosylceramide gl3 deposition in capillary endothelium of the kidney and certain other cell types 1,",3
"dantrolene sodium capsules are indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders eg spinal cord injury stroke cerebral palsy or multiple sclerosis it is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function dantrolene sodium capsules are not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders if improvement occurs it will ordinarily occur within the dosage titration see n dosage and administration occasionally subtle but meaningful improvement in spasticity may occur with dantrolene sodium capsule therapy in such instances information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him brief withdrawal of dantrolene sodium capsules for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impression a decision to continue the administration of dantrolene sodium capsules on a longterm basis is justified if introduction of the drug into the patients regimen n xa0xa0produces a significant reduction in painful andor disabling spasticity such as clonus or none xa0xa0permits a significant reduction in the intensity andor degree of nursing care required or none xa0xa0rids the patient of any annoying manifestation of spasticity considered important by the patient himself oral dantrolene sodium capsules are also indicated preoperatively to prevent or attenuate the development of signs of malignant hyperthermia in known or strongly suspect malignant hyperthermia susceptible patients who require anesthesia andor surgery currently accepted clinical practices in the management of such patients must still be adhered to careful monitoring for early signs of malignant hyperthermia minimizing exposure to triggering mechanisms and prompt use of intravenous dantrolene sodium and indicated supportive measures should signs of malignant hyperthermia appear see also the package insert for intravenous dantrolene sodium oral dantrolene sodium capsules should be administered following a malignant hyperthermic crisis to prevent recurrence of the signs of malignant hyperthermia,",2
"hyoscyamine sulfate is effective as adjunctive therapy in the treatment of peptic ulcer it can also be used to control gastric secretion visceral spasm and hypermotility in spastic colitis spastic bladder cystitis pylorospasm and associated abdominal cramps may be used in functional intestinal disorders to reduce symptoms such as those seen in mild dysenteries diverticulitis and acute enterocolitis for use as adjunctive therapy in the treatment of irritable bowel syndrome irritable colon spastic colon mucous colitis and functional gastrointestinal disorders also used as adjunctive therapy in the treatment of neurogenic bladder and neurogenic bowel disturbances including the splenic flexure syndrome and neurogenic colon also used in the treatment of infant colic elixir and drops hyoscyamine sulfate is indicated along with morphine or other narcotics in symptomatic relief of biliary and renal colic as a drying agent in the relief of symptoms of acute rhinitis in the therapy of parkinsonism to reduce rigidity and tremors and to control associated sialorrhea and hyperhidrosis may be used in the therapy of poisoning by anticholinesterase agents,",2
"n 11 supraventricular tachycardia or noncompensatory sinus tachycardia esmolol hydrochloride injection is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative postoperative or other emergent circumstances where short term control of ventricular rate with a shortacting agent is desirable esmolol hydrochloride injection is also indicated in noncompensatory sinus tachycardia where in the physician judgment the rapid heart rate requires specific intervention esmolol hydrochloride injection is intended for shortterm use n 12 intraoperative and postoperative tachycardia and hypertension esmolol hydrochloride injection is indicated for the shortterm treatment of tachycardia and hypertension that occur during induction and tracheal intubation during surgery on emergence from anesthesia and in the postoperative period when in the physician judgment such specific intervention is considered indicated none none esmolol hydrochloride injection is a beta adrenergic blocker indicated for the shortterm treatment of n control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardiaxa011 control of perioperative tachycardia and hypertensionxa012,",3
"carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see n n n n warnings sulindac tabletsxa0uspxa0are indicated for acute orxa0longterm use in the relief of signs and symptoms of the following n n osteoarthritis n rheumatoid arthritis n ankylosing spondylitis n acute painful shoulder acute subacromial bursitissupraspinatus tendinitis n acute gouty arthritis n none n n xa0 the safety and effectiveness of sulindac have not been established in rheumatoid arthritis patients who are designated in the american rheumatism association classification as functional class iv incapacitated largely or wholly bedridden or confined to wheelchair little or no selfcare,",2
"when oral therapy is not feasible the intramuscular usecontrol of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis serum sickness transfusion reactionsbullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus severe erythema multiforme stevensjohnson syndromecongenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditishydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importanceto tide the patient over a critical period of the disease in regional enteritis and ulcerative colitisacquired autoimmune hemolytic anemia diamondblackfan anemia pure red cell aplasia selected cases of secondary thrombocytopeniatrichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapyfor palliative management of leukemias and lymphomasacute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor or craniotomysympathetic ophthalmia temporal arteritis uveitis and ocular inflammatory conditions unresponsive to topical corticosteroidsto induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosusberylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosisas adjunctive therapy for shortterm administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require lowdose maintenance therapy for the treatment of dermatomyositis polymyositis and systemic lupus erythematosusthe intraarticular or soft tissue administrationthe intralesional administrationbetamethasone sodium phosphate and betamethasone acetate injectable suspension may also be useful in cystic tumors of an aponeurosis or tendon ganglia,",2
"cilostazol tablets usp are indicated for the reduction of symptoms of intermittent claudication as demonstrated by an increased walking distancecilostazol tablets usp are a phosphodiesterase iii inhibitor pde iii inhibitor indicated for the reduction of symptoms of intermittent claudication as demonstrated by an increased walking distance 1,",2
"azelastine hydrochloride nasal spray is indicated for the treatment of the symptoms of seasonal allergic rhinitis in adults and pediatric patients 5 years and older and for the treatment of the symptoms of vasomotor rhinitis in adults and adolescent patients 12 years and olderazelastine hydrochloride nasal spray is an h1receptor antagonist indicated for the treatment of the symptoms of seasonal allergic rhinitis in adults and pediatric patients 5 years and older and for the treatment of the symptoms of vasomotor rhinitis in adults and adolescent patients 12 years and older 1,",2
"based on a review of this drug by the national academy of sciencesnational research andor other information the fda has classified the indications as follows for the relief of symptoms associated with cerebrovascular insufficiencyin peripheral vascular disease of arteriosclerosis obliterans thromboangitis obliterans buergers disease and raynauds disease final classification of the lessthaneffective indications requires further investigation,",2
"diazepam is indicated for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolyticin acute alcohol withdrawal diazepam may be useful in the symptomatic relief of acute agitation tremor impending or acute delirium tremens and hallucinosisas an adjunct prior to endoscopic procedures if apprehension anxiety or acute stress reactions are present and to diminish the patients recall of the procedures see warningsdiazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology such as inflammation of the muscles or joints or secondary to trauma spasticity caused by upper motor neuron disorders such as cerebral palsy and paraplegia athetosis stiffman syndrome and tetanusinjectable diazepam is a useful adjunct in status epilepticus and severe recurrent convulsive seizuresdiazepam is a useful premedication the intramuscular route is preferred for relief of anxiety and tension in patients who are to undergo surgical procedures intravenously prior to cardioversion for the relief of anxiety and tension and to diminish the patients recall of the procedure,",2
"bumetanide tablets usp are indicated for the treatment of edema associated with congestive heart failure hepatic and renal disease including the nephrotic syndromealmost equal diuretic response occurs after oral and parenteral administration of bumetanide therefore if impaired gastrointestinal absorption is suspected or oral administration is not practical bumetanide should be given by the intramuscular or intravenous route successful treatment with bumetanide tablets usp following instances of allergic reactions to furosemide suggests a lack of crosssensitivitybumetanide is contraindicated in anuria although bumetanide tablets can be used to induce diuresis in renal insufficiency any marked increase in blood urea nitrogen or creatinine or the development of oliguria during therapy of patients with progressive renal disease is an indication for discontinuation of treatment with bumetanide tablets bumetanide is also contraindicated in patients in hepatic coma or in states of severe electrolyte depletion until the condition is improved or corrected bumetanide is contraindicated in patients hypersensitive to this drug,",2
"mitoxantrone injection usp concentrate is indicated for reducing neurologic disability andor the frequency of clinical relapses in patients with secondary chronic progressive progressive relapsing or worsening relapsingremitting multiple sclerosis ie patients whose neurologic status is significantly abnormal between relapses mitoxantrone injection usp concentrate is not indicated in the treatment of patients with primary progressive multiple sclerosis the clinical patterns of multiple sclerosis in the studies were characterized as follows secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses and worsening relapsingremitting disease was characterized by clinical relapses resulting in a stepwise worsening of disability mitoxantrone injection usp concentrate in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormonerefractory prostate cancer mitoxantrone injection usp concentrate in combination with other approved drugs is indicated in the initial therapy of acute nonlymphocytic leukemia anll in adults this category includes myelogenous promyelocytic monocytic and erythroid acute leukemias,",2
"the use of metoclopramide tablets usp is recommended for adults only therapy should not exceed 12 weeks in durationsymptomatic gastroesophageal reflux metoclopramide tablets usp are indicated as shortterm 4 to 12 weeks therapy for adults with symptomatic documented gastroesophageal reflux who fail to respond to conventional therapythe principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms if symptoms are confined to particular situations such as following the evening meal use of metoclopramide as single doses prior to the provocative situation should be considered rather than using the drug throughout the day healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12week trial using doses of 15 mg qid as there is no documented correlation between symptoms and healing of esophageal lesions patients with documented lesions should be monitored endoscopicallydiabetic gastroparesis diabetic gastric stasis metoclopramide tablets usp are indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis the usual manifestations of delayed gastric emptying eg nausea vomiting heartburn persistent fullness after meals and anorexia appear to respond to metoclopramide within different time intervals significant relief of nausea occurs early and continues to improve over a threeweek period relief of vomiting and anorexia may precede the relief of abdominal fullness by one week or more,",2
"clemastine fumarate tablets 134 mg are indicated for the relief of symptoms associated with allergic rhinitis such as sneezing rhinorrhea pruritus and lacrimationclemastine fumarate tablets 268 mg are indicated for the relief of symptoms associated with allergic rhinitis such as sneezing rhinorrhea pruritus and lacrimation clemastine fumarate tablets 268 mg are also indicated for the relief of mild uncomplicated allergic skin manifestations of urticaria and angioedemait should be noted that clemastine fumarate is indicated for the dermatologic indications at the 268 mg dosage level only,",2
"oxaprozin tablets are indicated n for relief of the signs and symptoms of osteoarthritis for relief of the signs and symptoms of rheumatoid arthritis for relief of the signs and symptoms of juvenile rheumatoid arthritis none oxaprozin is a nonsteroidal antiinflammatory drug indicated for n relief of signs and symptoms of osteoarthritis oa 1 relief of signs and symptoms of rheumatoid arthritis ra 1 relief of signs and symptoms of juvenile rheumatoid arthritis jra 1 none,",2
"carefully consider the potential benefits and risks of tolmetin sodium capsules usp and other treatment options before deciding to use tolmetin sodium capsules use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warningstolmetin sodium capsules are indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis tolmetin sodium capsules are indicated in the treatment of acute flares and the longterm management of the chronic diseasetolmetin sodium capsules are also indicated for treatment of juvenile rheumatoid arthritis the safety and effectiveness of tolmetin sodium capsules have not been established in pediatric patients under 2 years of age see precautions pediatric usedosage and administration,",2
"mometasone furoate monohydrate nasal spray is a corticosteroid indicated for1 treatment of nasal symptoms of allergic rhinitis in patients 2 years of age 112 treatment of nasal congestion associated with seasonal allergic rhinitis in patients 2 years of age 123 prophylaxis of seasonal allergic rhinitis in patients 12 years of age 134 treatment of nasal polyps in patients 18 years of age 14mometasone furoate monohydrate nasal spray 50 mcg is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis in adults and pediatric patients 2 years of age and oldermometasone furoate monohydrate nasal spray 50 mcg is indicated for the relief of nasal congestion associated with seasonal allergic rhinitis in adults and pediatric patients 2 years of age and oldermometasone furoate monohydrate nasal spray 50 mcg is indicated for the prophylaxis of the nasal symptoms of seasonal allergic rhinitis in adult and adolescent patients 12 years and oldermometasone furoate monohydrate nasal spray 50 mcg is indicated for the treatment of nasal polyps in patients 18 years of age and older,",3
"cetirizine hydrochloride syrup is indicated for the relief of symptoms associated with perennial allergic rhinitis due to allergens such as dust mites animal dander and molds in children 6 to 23 months of age symptoms treated effectively include sneezing rhinorrhea postnasal discharge nasal pruritus ocular pruritus and tearing cetirizine hydrochloride syrup is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months to 5 years of age it significantly reduces the occurrence severity and duration of hives and significantly reduces pruritus,",2
"hyoscyamine sulfate is effective as adjunctive therapy in the treatment of peptic ulcer it can also be used to control gastric secretion visceral spasm and hypermotility in spastic colitis spastic bladder cystitis pylorospasm and associated abdominal cramps may be used in functional intestinal disorders to reduce symptoms such as those seen in mild dysenteries diverticulitis and acute enterocolitis for use as adjunctive therapy in the treatment of irritable bowel syndrome irritable colon spastic colon mucous colitis and functional gastrointestinal disorders also used as adjunctive therapy in the treatment of neurogenic bladder and neurogenic bowel disturbances including the splenic flexure syndrome and neurogenic colon also used in the treatment of infant colic elixir and drops hyoscyamine sulfate is indicated along with morphine or other narcotics in symptomatic relief of biliary and renal colic as a drying agent in the relief of symptoms of acute rhinitis in the therapy of parkinsonism to reduce rigidity and tremors and to control associated sialorrhea and hyperhidrosis may be used in the therapy of poisoning by anticholinesterase agents,",2
"oxandrolone tablets usp are indicated as adjunctive therapy to promote weight gain after weight loss following extensive surgery chronic infections or severe trauma and in some patients who without definite pathophysiologic reasons fail to gain or to maintain normal weight to offset the protein catabolism associated with prolonged administration of corticosteroids and for the relief of the bone pain frequently accompanying osteoporosis see dosage and administration,",2
"loperamide hydrochloride capsules are indicated for the control and symptomatic relief of acute nonspecific diarrhea in patients 2 years of age and older and of chronic diarrhea in adults associated with inflammatory bowel disease loperamide hydrochloride capsules are also indicated for reducing the volume of discharge from ileostomies,",2
"flunisolide nasal solution is indicated for the treatment of the nasal symptoms of seasonal or perennial rhinitis flunisolide nasal solution should not be used in the presence of untreated localized infection involving the nasal mucosa,",2
"none montelukast sodium tablets are a leukotriene receptor antagonist indicated for n prophylaxis and chronic treatment of asthma in patients 2 years of age and older 11 acute prevention of exerciseinduced bronchoconstriction eib in patients 15 years of age and older 12 relief of symptoms of allergic rhinitis ar seasonal allergic rhinitis sar in patients 2 years of age and older and perennial allergic rhinitis par in patients 2 years of age and older 13 montelukast sodium is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 2 years of age and older montelukast sodium is indicated for prevention of exerciseinduced bronchoconstriction eib in patients 15 years of age and older n pediatric use information for patients ages 6 to 14 years of age for acute prevention of exerciseinduced bronchoconstriction eib is approved for merck sharp dohme corp montelukast tablet products however due to merck sharp dohme corp marketing exclusivity rights this drug product is not labeled with that pediatric information montelukast sodium is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 2 years of age and older,",2
"parenteral sedativeshypnotics for the shortterm treatment of insomnia since they appear to lose their effectiveness for sleep induction and sleep maintenance after 2 weeks see clinical pharmacologypreanestheticsanticonvulsant in anesthetic doses in the emergency control of certain acute convulsive episodes eg those associated with status epilepticus cholera eclampsia meningitis tetanus and toxic reactions to strychnine or local anesthetics,",2
"azelastine hydrochloride nasal spray is indicated for the treatment of the symptoms of seasonal allergic rhinitis in adults and pediatric patients 5 years and older and for the treatment of the symptoms of vasomotor rhinitis in adults and adolescent patients 12 years and olderazelastine hydrochloride nasal spray is an h1receptor antagonist indicated for the treatment of the symptoms of seasonal allergic rhinitis in adults and pediatric patients 5 years and older and for the treatment of the symptoms of vasomotor rhinitis in adults and adolescent patients 12 years and older 1,",2
"fexofenadine hydrochloride is an h1receptor antagonist indicated for relief of symptoms associated with seasonal allergic rhinitis in patients 6 years of age and older 11 treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in patients 6 years of age and older 12fexofenadine hydrochloride tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older fexofenadine hydrochloride tablets are indicated for treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 of age and older,",2
"carefully consider the potential benefits and risks of etodolac extendedrelease tablets usp and other treatment options before deciding to use etodolac extendedrelease tablets usp use the lowest effective dose for the shortest duration consistent with individual patient treatment goals see warningsetodolac extendedrelease tablets usp are indicated for relief of signs and symptoms of juvenile arthritis for relief of the signs and symptoms of rheumatoid arthritis for relief of the signs and symptoms of osteoarthritis,",2
"bexarotene capsules are indicated for the treatment of cutaneous manifestations of cutaneous tcell lymphoma in patients who are refractory to at least one prior systemic therapy bexarotene capsules are a retinoid indicated for the treatment of cutaneous manifestations of cutaneous tcell lymphoma in patients who are refractory to at least one prior systemic therapy,",3
"flavoxate hydrochloride tablets are indicated for symptomatic relief of dysuria urgency nocturia suprapubic pain frequency and incontinence as may occur in cystitis prostatitis urethritis urethrocystitis urethrotrigonitis flavoxate hydrochloride tablets are not indicated for definitive treatment but are compatible with drugs used for the treatment of urinary tract infections,",2
"flavoxate hydrochloride tablets are indicated for symptomatic relief of dysuria urgency nocturia suprapubic pain frequency and incontinence as may occur in cystitis prostatitis urethritis urethrocystitis urethrotrigonitis flavoxate hydrochloride tablets are not indicated for definitive treatment but are compatible with drugs used for the treatment of urinary tract infections,",2
"korlym mifepristone is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushings syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgeryn limitations of usen n korlym should not be used in the treatment of patients with type 2 diabetes unless it is secondary to cushings syndromen korlym mifepristone is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushings syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery 1 none none n n important limitations of use,",2
"zontivity is a proteaseactivated receptor1 par1 antagonist indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction mi or with peripheral arterial disease pad zontivity has been shown to reduce the rate of a combined endpoint of cardiovascular death mi stroke and urgent coronary revascularization 11zontivity,",2
"panretin gel is indicated for topical treatment of cutaneous lesions in patients with aidsrelated kaposi sarcoma panretin gel is not indicated when systemic antiks therapy is required eg more than 10 new ks lesions in the prior month symptomatic lymphedema symptomatic pulmonary ks or symptomatic visceral involvement there is no experience to date using panretin gel with systemic antiks treatment,",2
"clotrimazole lozenges are indicated for the local treatment of oropharyngeal candidiasis the diagnoses should be confirmed by a koh smear andor culture prior to treatmentclotrimazole lozenges are also indicated prophylactically to reduce the incidence of oropharyngeal candidiasis in patients immunocompromised by conditions that include chemotherapy radiotherapy or steroid therapy utilized in the treatment of leukemia solid tumors or renal transplantation there are no data from adequate and wellcontrolled trials to establish the safety and efficacy of this product for prophylactic use in patients immunocompromised by etiologies other than those listed in the previous sentence see dosage and administration,",2
"flavoxate hydrochloride tablets are indicated for symptomatic relief of dysuria urgency nocturia suprapubic pain frequency and incontinence as may occur in cystitis prostatitis urethritis urethrocystitis urethrotrigonitis flavoxate hydrochloride tablets are not indicated for definitive treatment but are compatible with drugs used for the treatment of urinary tract infections,",2
"patients should not be treated with epirubicin hydrochloride injection if they have any of the following conditions cardiomyopathy andor heart failure recent myocardial infarction or severe arrhythmias see warnings and precautions 53 previous treatment with maximum cumulative dose of anthracyclines see warnings and precautions 5 hypersensitivity to epirubicin hydrochloride injection other anthracyclines or anthracenediones see adverse reactions 62 patients should not be treated with epirubicin hydrochloride injection if they have any of the following conditions baseline neutrophil count????????????less than 1500 cellsmm 3 4,",1
"tolterodine tartrate extendedrelease capsules are contraindicated in patients with urinary retention gastric retention or uncontrolled narrowangle glaucoma tolterodine tartrate extendedrelease capsulesare also contraindicated in patients with known hypersensitivity to the drug or its ingredients or to fesoterodine fumarate extendedrelease tablets which like tolterodine tartrate extendedrelease capsules are metabolized to 5hydroxymethyl tolterodine see warnings and precautions 52 53 54 tolterodine tartrate extendedrelease capsules are contraindicated in patients with urinary retention gastric retention or uncontrolled narrowangle glaucoma tolterodine tartrate extendedrelease capsules are also contraindicated in patients with known hypersensitivity to the drug or its ingredients or to fesoterodine fumarate extendedrelease tablets which like tolterodine tartrate extendedrelease capsules are metabolized to 5hydroxymethyl tolterodine 4,",1
"in patients who are hypersensitive to the drug or its ingredients phenazopyridine is contraindicated in patients with renal insufficiency severe liver disease severe hepatitis or pyelonephritis of pregnancy it should be used cautiously in the presence of gi disturbances,",1
"pyrazinamide is contraindicated in persons with severe hepatic damage who have shown hypersensitivity to it with acute gout,",1
"administration is contraindicated in patients with any of the following hypersensitivity to cycloserine epilepsy depression severe anxiety or psychosis severe renal insufficiency excessive concurrent use of alcohol,",1
"none eszopiclone is contraindicated in patients with known hypersensitivity to eszopiclone hypersensitivity reactions include anaphylaxis and angioedema see warnings and precautions 52 none known hypersensitivity to eszopiclone 4,",1
"anuria hypersensitivity to any component of this product or to other sulfonamidederived drugs,",1
"pindolol tablets are contraindicated in 1 bronchial asthma 2 overt cardiac failure 3 cardiogenic shock 4 second and third degree heart block 5 severe bradycardia see warnings,",1
"n ocular or periocular infections 41 none glaucoma 42 none torn or ruptured posterior lens capsule 43 none hypersensitivity 44 n ozurdex n xa0 n ozurdex n n ozurdex ozurdex n ozurdex n see adverse reactions n 6,",1
"known hypersensitivity or idiosyncratic reactions to sympathomimetics advanced arteriosclerosis symptomatic cardiovascular disease moderate and severe hypertension hyperthyroidism and glaucoma highly nervous or agitated patients patients with a history of drug abuse patients taking other cns stimulants including monoamine oxidase inhibitors tolerance to the anorectic effect of phendimetrazine develops within a few weeks when this occurs its use should be discontinued the maximum recommended dose should not be exceeded use of phendimetrazine tartrate within 14 days following the administration of monoamine oxidase inhibitors may result in a hypertensive crisis abrupt cessation of administration following prolonged high dosage results in extreme fatigue and depression because of the effect on the central nervous system phendimetrazine may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle the patient should therefore be cautioned accordingly,",1
"none hypersensitivity to hydralazine coronary artery disease mitral valvular rheumatic heart disease,",1
"propafenone hydrochloride is contraindicated in the following circumstances n heart failure none cardiogenic shock none sinoatrial atrioventricular and intraventricular disorders of impulse generation or conductionxa0eg sick sinus node syndrome av block in the absence of an artificial pacemaker none known brugada syndrome none bradycardia none marked hypotension none bronchospastic disorders or severe obstructive pulmonary disease none marked electrolyte imbalance n heart failure 4 cardiogenic shock 4 sinoatrial atrioventricular and intraventricular disorders of impulse generation or conduction in the absence of pacemaker 4 none known brugada syndrome 4 none bradycardia 4 marked hypotension 4 bronchospastic disorders and severe obstructive pulmonary disease 4 none marked electrolyte imbalance 4,",1
"hypersensitivity to bromocriptine or to any of the excipients of bromocriptine mesylate tablets or capsules uncontrolled hypertension and sensitivity to any ergot alkaloids in patients being treated for hyperprolactinemia bromocriptine mesylate tablets and capsules should be withdrawn when pregnancy is diagnosed see precautions hyperprolactinemic states in the event that bromocriptine is reinstituted to control a rapidly expanding macroadenoma see precautions hyperprolactinemic statesand a patient experiences a hypertensive disorder of pregnancy the benefit of continuing bromocriptine must be weighed against the possible risk of its use during a hypertensive disorder of pregnancy when bromocriptine is being used to treat acromegaly prolactinoma or parkinson disease in patients who subsequently become pregnant a decision should be made as to whether the therapy continues to be medically necessary or can be withdrawn if it is continued the drug should be withdrawn in those who may experience hypertensive disorders of pregnancy including eclampsia preeclampsia or pregnancyinduced hypertension unless withdrawal of bromocriptine is considered to be medically contraindicated the drug should not be used during the postpartum period in women with a history of coronary artery disease and other severe cardiovascular conditions unless withdrawal is considered medically contraindicated if the drug is used in the postpartum period the patient should be observed with caution,",1
"cleviprex is contraindicated in patients with allergy to soy or eggs 41 defective lipid metabolism 42 severe aortic stenosis 43 cleviprex is contraindicated in patients with allergies to soybeans soy products eggs or egg products cleviprex is contraindicated in patients with defective lipid metabolism such as pathologic hyperlipemia lipoid nephrosis or acute pancreatitis if it is accompanied by hyperlipidemia cleviprex is contraindicated in patients with severe aortic stenosis because afterload reduction can be expected to reduce myocardial oxygen delivery,",1
"antepartum use of pitocin is contraindicated in any of the following circumstances where there is significant cephalopelvic disproportion in unfavorable fetal positions or presentations such as transverse lies which are undeliverable without conversion prior to delivery in obstetrical emergencies where the benefittorisk ratio for either the fetus or the mother favors surgical intervention in fetal distress where delivery is not imminent where adequate uterine activity fails to achieve satisfactory progress where the uterus is already hyperactive or hypertonic in cases where vaginal delivery is contraindicated such as invasive cervical carcinoma active herpes genitalis total placenta previa vasa previa and cord presentation or prolapse of the cord in patients with hypersensitivity to the drug,",1
"nadolol tablets are contraindicated in bronchial asthma sinus bradycardia and greater than first degree conduction block cardiogenic shock and overt cardiac failure see warnings,",1
"miglitol tablets are contraindicated in patients with diabetic ketoacidosis inflammatory bowel disease colonic ulceration or partial intestinal obstruction and in patients predisposed to intestinal obstruction chronic intestinal diseases associated with marked disorders of digestion or absorption or with conditions that may deteriorate as a result of increased gas formation in the intestine hypersensitivity to the drug or any of its components,",1
"rizatriptan benzoate tablets are contraindicated in patients with n ischemic coronary artery disease angina pectoris history of myocardial infarction or documented silent ischemia or other significant underlying cardiovascular disease n n n see n n n warnings and precautions 51 coronary artery vasospasm including prinzmetals angina n n n see n n n warnings and precautions 51 history of stroke or transient ischemic attack tia n n n see n n n warnings and precautions 54 peripheral vascular disease pvdn n n see n n n warnings and precautions 55 ischemic bowel disease n n n see n n n warnings and precautions 55 uncontrolled hypertension n n n see n n n warnings and precautions 58 recent use ie within 24 hours of another 5htn n n 1 see n n n drug interactions 72 73 hemiplegic or basilar migraine concurrent administration or recent discontinuation ie within 2 weeks of a maoa inhibitor n n n seexa0n n n drug interactions 75 clinical pharmacology 123 hypersensitivity to rizatriptan benzoate tablets angioedema and anaphylaxis seen n n n see n n n adverse reactions 62 n history of ischemic heart disease or coronary artery vasospasm n n n 4 history of stroke or transient ischemic attack n n n 4 peripheral vascular disease n n n 4 ischemic bowel disease n n n 4 uncontrolled hypertension n n n 4 recent within 24 hours use of another 5htn n n 1 4 hemiplegic or basilar migraine n n n 4 maoa inhibitor used in the past 2 weeks n n n 4 hypersensitivity to rizatriptan n n n none none 4,",1
"hypersensitivity to any component of this product dactinomycin for injection should not be given at or about the time of infection with chickenpox or herpes zoster because of the risk of severe generalized disease which may result in death,",1
"glaucoma obstructive uropathy for example bladder neck obstruction due to prostatic hypertrophy obstructive disease of the gastrointestinal tract as in achalasia pyloroduodenal stenosis paralytic ileus intestinal atony of elderly or debilitated patients unstable cardiovascular status in acute hemorrhage severe ulcerative colitis toxic megacolon complicating ulcerative colitis myasthenia gravis and myocardial ischemia,",1
"do not initiate in patients with constipation 41 history of chronic or severe constipation or sequelae from constipation intestinal obstruction stricture toxic megacolon gastrointestinal perforation andor adhesions ischemic colitis impaired intestinal circulation thrombophlebitis or hypercoagulable state crohns disease or ulcerative colitis diverticulitis severe hepatic impairment 42 concomitant use of fluvoxamine 43 alosetron hydrochloride should not be initiated see warnings and precautions 51 alosetron hydrochloride is contraindicated in patients with a history of the following chronic or severe constipation or sequelae from constipation intestinal obstruction stricture toxic megacolon gastrointestinal perforation andor adhesions ischemic colitis impaired intestinal circulation thrombophlebitis or hypercoagulable state crohns disease or ulcerative colitis diverticulitis severe hepatic impairment concomitant administration of alosetron hydrochloride with fluvoxamine is contraindicated fluvoxamine a known strong inhibitor of cyp1a2 has been shown to increase mean alosetron plasma concentrations auc approximately 6fold and prolong the halflife by approximately 3fold see drug interactions 71,",1
"n history of cardiovascular disease eg coronary artery disease stroke arrhythmias congestive heart failure uncontrolled hypertension during or within 14 days following the administration of monoamine oxidase inhibitors hyperthyroidism glaucoma agitated states history of drug abuse pregnancy see n n n n use in specific populations 81 nursing see n n n n use in specific populations 83 known hypersensitivity or idiosyncrasy to the sympathomimetic amines n history of cardiovascular disease eg coronary artery disease stroke arrhythmias congestive heart failure uncontrolled hypertension n n n none 4 during or within 14 days following the administration of monoamine oxidase inhibitors n n n none 4 hyperthyroidism n n n none 4 glaucoma n n n none 4 agitated states n n n none 4 history of drug abuse n n n 4 pregnancy n n n 4 81 nursing n n n 4 83 known hypersensitivity or idiosyncrasy to the sympathomimetic amines n n n none none 4,",1
"aminocaproic acid should not be used when there is evidence of an active intravascular clotting process when there is uncertainty as to whether the cause of bleeding is primary fibrinolysis or disseminated intravascular coagulation dic this distinction must be made before administering aminocaproic acid injection the following tests can be applied to differentiate the two conditions platelet count is usually decreased in dic but normal in primary fibrinolysis protamine paracoagulation test is positive in dic a precipitate forms when protamine sulfate is dropped into citrated plasma the test is negative in the presence of primary fibrinolysis the euglobulin clot lysis test is abnormal in primary fibrinolysis but normal in dic aminocaproic acid injection must not be used in the presence of dic without concomitant heparin,",1
"ocular or periocular infections 41 hypersensitivity 42 yutiq is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including active epithelial herpes simplex keratitis dendritic keratitis vaccinia varicella mycobacterial infections and fungal diseases yutiq is contraindicated in patients with known hypersensitivity to any components of this product,",1
"n contraindications patients with allergy to these drugs or other analogues diclofenac patients with asthma like nsaids acetylsalicylic acid and other drugs which inhibit prostagladinsynthesis may precipitate attacks of asthma acute rhinitis or urticaria patients with active peptic ulcer none,",1
"adenosine injection is contraindicated in patients with none n second or thirddegree av block except in patients with a functioning artificial pacemaker see warnings and precautions 52 sinus node disease such as sick sinus syndrome or symptomatic bradycardia except in patients with a functioning artificial pacemaker see warnings and precautions 52 known or suspected bronchoconstrictive or bronchospastic lung disease eg asthma see warnings and precautions 53 known hypersensitivity to adenosine injection see warnings and precautions 57 n second or thirddegree av block except in patients with a functioning artificial pacemaker 4 sinus node disease such as sick sinus syndrome or symptomatic bradycardia except in patients with a functioning artificial pacemaker 4 known or suspected bronchoconstrictive or bronchospastic lung disease eg asthma 4 known hypersensitivity to adenosine injection 4,",1
"sotalol hydrochloride is contraindicated in patients with sinus bradycardia sick sinus syndrome second and third degree av block unless a functioning pacemaker is present congenital or acquired long qt syndromes cardiogenic shock or decompensated heart failure serum potassium 4 meql bronchial asthma or related bronchospastic conditions hypersensitivity to sotalol for the treatment of afibafl sotalol hydrochloride is also contraindicated in patients with baseline qt interval 450 ms creatinine clearance 40 mlmin for the treatment of afibafl or ventricular arrhythmias sinus bradycardia 2 nd rd 4 congenital or acquired long qt syndrome 4 serum potassium 4 meql 4 cardiogenic shock decompensated heart failure 4 bronchial asthma or related bronchospastic conditions 4 hypersensitivity to sotalol 4 for the treatment of afibafl also contraindicated for qt interval 450 ms 4 creatine clearance 40 mlmin 4,",1
"rizatriptan benzoate tablets are contraindicated in patients with n ischemic coronary artery disease angina pectoris history of myocardial infarction or documented silent ischemia or other significant underlying cardiovascular disease n n n see n n n warnings and precautions 51 coronary artery vasospasm including prinzmetals angina n n n see n n n warnings and precautions 51 history of stroke or transient ischemic attack tia n n n see n n n warnings and precautions 54 peripheral vascular disease pvdn n n see n n n warnings and precautions 55 ischemic bowel disease n n n see n n n warnings and precautions 55 uncontrolled hypertension n n n see n n n warnings and precautions 58 recent use ie within 24 hours of another 5htn n n 1 see n n n drug interactions 72 73 hemiplegic or basilar migraine concurrent administration or recent discontinuation ie within 2 weeks of a maoa inhibitor n n n seexa0n n n drug interactions 75 clinical pharmacology 123 hypersensitivity to rizatriptan benzoate tablets angioedema and anaphylaxis seen n n n see n n n adverse reactions 62 n history of ischemic heart disease or coronary artery vasospasm n n n 4 history of stroke or transient ischemic attack n n n 4 peripheral vascular disease n n n 4 ischemic bowel disease n n n 4 uncontrolled hypertension n n n 4 recent within 24 hours use of another 5htn n n 1 4 hemiplegic or basilar migraine n n n 4 maoa inhibitor used in the past 2 weeks n n n 4 hypersensitivity to rizatriptan n n n none none 4,",1
"trulicity is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome type 2 4 51 trulicity is contraindicated in patients with a prior serious hypersensitivity reaction to trulicity or any of the product components 4 54  medullary thyroid carcinoma trulicity is contraindicated in patients with a personal or family history of medullary thyroid carcinoma mtc or in patients with multiple endocrine neoplasia syndrome type 2 men 2 see warnings and precautions 51  hypersensitivity trulicity is contraindicated in patients with a prior serious hypersensitivity reaction to dulaglutide or to any of the product components serious hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with trulicity see warnings and precautions 54,",1
"gilenya is contraindicated in patients who have in the last 6 months experienced myocardial infarction unstable angina stroke tia decompensated heart failure requiring hospitalization or class iiiiv heart failure a history or presence of mobitz type ii seconddegree or thirddegree av block or sick sinus syndrome unless patient has a functioning pacemaker see warnings and precautions 51 a baseline qtc interval 500 msec cardiac arrhythmias requiring antiarrhythmic treatment with class ia or class iii antiarrhythmic drugs had a hypersensitivity reaction to fingolimod or any of the excipients in gilenya observed reactions include rash urticaria and angioedema upon treatment initiation see warnings and precautions 513 recent myocardial infarction unstable angina stroke transient ischemic attack decompensated heart failure with hospitalization or class iiiiv heart failure 4 history of mobitz type ii 2 nd rd 4 baseline qtc interval  500 msec 4 cardiac arrhythmias requiring antiarrhythmic treatment with class ia or class iii antiarrhythmic drugs 4 hypersensitivity to fingolimod or its excipients 4,",1
"torsemide tablets are contraindicated in patients with known hypersensitivity to torsemide tablets or to povidone torsemide tablets are contraindicated in patients who are anuric torsemide tablets are contraindicated in patients with hepatic coma hypersensitivity to torsemide tablets or povidone anuria and hepatic coma 4,",1
"methyldopa is contraindicated in patients with active hepatic disease such as acute hepatitis and active cirrhosis with liver disorders previously associated with methyldopa therapy see warnings with hypersensitivity to any component of this product on therapy with monoamine oxidase mao inhibitors,",1
"lindane shampoo is contraindicated in premature infants and individuals with known uncontrolled seizure disorders lindane shampoo is contraindicated for premature infants because their skin may be more permeable than that of full term infants and their liver enzymes may not be sufficiently developed to metabolize lindane lindane shampoo is also contraindicated for patients with crusted norwegian scabies and other skin conditions eg atopic dermatitis psoriasis that may increase systemic absorption of the drug lindane shampoo is contraindicated for patients with known uncontrolled seizure disorders and for individuals with a known sensitivity to the product or any of its components,",1
"loperamide hydrochloride capsules are contraindicated in patients with a known hypersensitivity to loperamide hydrochloride or to any of the excipients loperamide hydrochloride is contraindicated in patients with abdominal pain in the absence of diarrhea loperamide hydrochloride is not recommended in infants below 24 months of age loperamide hydrochloride should not be used as the primary therapy in patients with acute dysentery which is characterized by blood in stools and high fever in patients with acute ulcerative colitis in patients with bacterial enterocolitis caused by invasive organisms including salmonella shigella and campylobacter in patients with pseudomembranous colitis associated with the use of broadspectrum antibiotics,",1
"n hypersensitivity to clarithromycin or any macrolide drug n n n 41 cisapride pimozide lovastatinsimvastatin ergotaminedihydroergotamine n n n 42 45 46 history of cholestatic jaundicehepatic dysfunction with use of clarithromycin n n n 43 colchicine in renal or hepatic impairment n n n 44 n hypersensitivity to clarithromycin or any macrolide drug n n n 41 cisapride pimozide lovastatinsimvastatin ergotaminedihydroergotamine n n n 42 45 46 history of cholestatic jaundicehepatic dysfunction with use of clarithromycin n n n 43 colchicine in renal or hepatic impairment n n n 44 clarithromycin tablets are contraindicated in patients with a known hypersensitivity to clarithromycin erythromycin or any of the macrolide antibacterial drugs n n n see n n n warnings and precautions 51 concomitant administration of clarithromycin tablets with cisapride and pimozide is contraindicated n n n see n n n drug interactions 7 none there have been postmarketing reports of drug interactions when clarithromycin is coadministered with cisapride or pimozide resulting in cardiac arrhythmias qt prolongation ventricular tachycardia ventricular fibrillation and n n n torsades de pointes clarithromycin tablets are contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of clarithromycin concomitant administration of clarithromycin tablets and colchicine is contraindicated in patients with renal or hepatic impairment do not use clarithromycin tablets concomitantly with hmgcoa reductase inhibitors statins that are extensively metabolized by cyp3a4 lovastatin or simvastatin due to the increased risk of myopathy including rhabdomyolysis n n n seexa0n n n warnings and precautions 54 drug interactions 7 concomitant administration of clarithromycin and ergotamine or dihydroergotamine is contraindicated n n n see n n n drug interactions 7 for information about contraindications of other drugs indicated in combination with clarithromycin tablets refer to their full prescribing information contraindications section,",0
"use of mefloquine hydrochloride tablets is contraindicated in patients with a known hypersensitivity to mefloquine or related compounds eg quinine and quinidine or to any of the excipients contained in the formulation mefloquine hydrochloride tablets should not be prescribed for prophylaxis in patients with active depression a recent history of depression generalized anxiety disorder psychosis or schizophrenia or other major psychiatric disorders or with a history of convulsions,",1
"doxapram is contraindicated in patients with known hypersensitivity to the drug or any of the injection components doxapram should not be used in patients with epilepsy or other convulsive disorders doxapram is contraindicated in patients with proven or suspected pulmonary embolism doxapram is contraindicated in patients with mechanical disorders of ventilation such as mechanical obstruction muscle paresis including neuromuscular blockade flail chest pneumothorax acute bronchial asthma pulmonary fibrosis or other conditions resulting in restriction of the chest wall muscles of respiration or alveolar expansion doxapram is contraindicated in patients with evidence of head injury cerebral vascular accident or cerebral edema and in those with significant cardiovascular impairment uncompensated heart failure severe coronary artery disease or severe hypertension including that associated with hyperthyroidism or pheochromocytoma see warnings,",1
"zafirlukast tablets are contraindicated in patients who are hypersensitive to zafirlukast or any of its inactive ingredients zafirlukast tablets are contraindicated in patients with hepatic impairment including hepatic cirrhosis,",1
"noctiva is contraindicated in patients with the following conditions due to an increased risk of severe hyponatremia hyponatremia or a history of hyponatremia see warnings and precautions 51 polydipsia primary nocturnal enuresis see use in specific populations 84 concomitant use with loop diuretics see warnings and precautions 51 concomitant use with systemic or inhaled glucocorticoids see warnings and precautions 51 71 renal impairment with an estimated glomerular filtration rate egfr below 50 mlmin173 m 2 see use in specific populations 86 known or suspected syndrome of inappropriate antidiuretic hormone siadh secretion during illnesses that can cause fluid or electrolyte imbalance such as gastroenteritis saltwasting nephropathies or systemic infection noctiva is contraindicated in patients with the following conditions because fluid retention increases the risk of worsening the underlying condition congestive heart failure new york heart association class ii to iv see warnings and precautions 52 uncontrolled hypertension hyponatremia or a history of hyponatremia 4 polydipsia 4 primary nocturnal enuresis 4 concomitant use with loop diuretics or systemic or inhaled glucocorticoids 4 estimated glomerular filtration rate below 50 mlmin173 m 2 4 syndrome of inappropriate antidiuretic hormone secretion siadh 4 during illnesses that can cause fluid or electrolyte imbalance 4 new york heart association nyha class iiiv congestive heart failure 4 uncontrolled hypertension 4,",1
"do not administer in the presence of diseases characterized by bleeding diathesis individuals with autoimmune disease may be at risk of exacerbating symptoms of the underlying disease possibly due to routine immunization patients who have experienced a recent myocardial infarction may not be tolerant of immunotherapy children with nephrotic syndrome probably should not receive injections due to immunization causing exacerbation of nephrotic disease,",1
"bumetanide is contraindicated in anuria although bumetanide tablets can be used to induce diuresis in renal insufficiency any marked increase in blood urea nitrogen or creatinine or the development of oliguria during therapy of patients with progressive renal disease is an indication for discontinuation of treatment with bumetanide tablets bumetanide is also contraindicated in patients in hepatic coma or in states of severe electrolyte depletion until the condition is improved or corrected bumetanide is contraindicated in patients hypersensitive to this drug,",1
"precocious puberty prostatic carcinoma or other androgendependent neoplasm prior allergic reaction to hcg hcg may cause fetal harm when administered to a pregnant woman combined hcgpms pregnant mares serum therapy has been noted to induce high incidences of external congenital anomalies in the offspring of mice in a dosedependent manner the potential extrapolation to humans has not been determined,",1
"tegsedi is contraindicated in patients with platelet count below 100 x 10 9 see warnings and precautions 51 history of acute glomerulonephritis caused by tegsedi see warnings and precautions 52 history of a hypersensitivity reaction to tegsedi see warnings and precautions 57 platelet count less than 100 x 10 9 4 51 history of acute glomerulonephritis caused by tegsedi 4 52 patients with a history of a hypersensitivity reaction to tegsedi 4 57,",1
"noctiva is contraindicated in patients with the following conditions due to an increased risk of severe hyponatremia hyponatremia or a history of hyponatremia see warnings and precautions 51 polydipsia primary nocturnal enuresis see use in specific populations 84 concomitant use with loop diuretics see warnings and precautions 51 concomitant use with systemic or inhaled glucocorticoids see warnings and precautions 51 71 renal impairment with an estimated glomerular filtration rate egfr below 50 mlmin173 m 2 see use in specific populations 86 known or suspected syndrome of inappropriate antidiuretic hormone siadh secretion during illnesses that can cause fluid or electrolyte imbalance such as gastroenteritis saltwasting nephropathies or systemic infection noctiva is contraindicated in patients with the following conditions because fluid retention increases the risk of worsening the underlying condition congestive heart failure new york heart association class ii to iv see warnings and precautions 52 uncontrolled hypertension hyponatremia or a history of hyponatremia 4 polydipsia 4 primary nocturnal enuresis 4 concomitant use with loop diuretics or systemic or inhaled glucocorticoids 4 estimated glomerular filtration rate below 50 mlmin173 m 2 4 syndrome of inappropriate antidiuretic hormone secretion siadh 4 during illnesses that can cause fluid or electrolyte imbalance 4 new york heart association nyha class iiiv congestive heart failure 4 uncontrolled hypertension 4,",1
"cuvposa is contraindicated in patients with medical conditions that preclude anticholinergic therapy eg glaucoma paralytic ileus unstable cardiovascular status in acute hemorrhage severe ulcerative colitis toxic megacolon complicating ulcerative colitis myasthenia gravis patients taking solid oral dosage forms of potassium chloride the passage of potassium chloride tablets through the gastrointestinal gi tract may be arrested or delayed with coadministration of cuvposa medical conditions that preclude anticholinergic therapy 4 concomitant use of solid oral dosage forms of potassium chloride 4,",1
"succinylcholine is contraindicated in persons with personal or familial history of malignant hyperthermia skeletal muscle myopathies and known hypersensitivity to the drug it is also contraindicated in patients after the acute phase of injury following major burns multiple trauma extensive denervation of skeletal muscle or upper motor neuron injury because succinylcholine administered to such individuals may result in severe hyperkalemia which may result in cardiac arrest see warnings,",0
"viberzixa0is contraindicated in patients n without a gallbladder these patients are at increased risk of developing serious adverse reactions of pancreatitis andor sphincter of oddi spasm see warnings and precautions 51 52 none with known or suspectedxa0biliary duct obstruction or sphincter of oddi disease or dysfunction these patients are at increased risk for sphincter of oddi spasm see warnings and precautions xa0 51 none with alcoholism alcohol abuse or alcohol addiction or in patients who drink more than 3 alcoholic beverages per day these patients are at increased risk for acute pancreatitis see warnings and precautions 51 none with a history of pancreatitisxa0or structural diseases of the pancreas including known or suspected pancreatic duct obstruction these patients are at increased risk for acute pancreatitisxa0 see warnings and precautions 51 none with a known hypersensitivity reaction to viberzi see warnings and precautions 53 none with severe hepatic impairment childpugh class cxa0these patients are at risk for significantly increased plasma concentrations of eluxadoline see use in specific populations 86 none with a history of chronic or severe constipation or sequelae from constipation or known or suspected mechanical gastrointestinal obstruction these patients may be at risk for severe complications of bowel obstructionxa0 see warnings and precautions 54 n patients without a gallbladder 4 none known or suspected biliary duct obstruction or sphincter of oddi disease or dysfunction 4 n alcoholism alcohol abuse alcohol addiction or drink more than 3 alcoholic beveragesday 4 none a history of pancreatitis structural diseases of the pancreas including known or suspected pancreatic duct obstruction 4 none patients with a known hypersensitivity reaction to viberzi 4 53 none severe hepatic impairment childpugh class c 4 86 none a history of chronic or severe constipation or sequelae from constipationxa0or known or suspected mechanical gastrointestinal obstruction 4,",1
"ketek is contraindicated in patients with myasthenia gravis ketek is contraindicated in patients with previous history of hepatitis andor jaundice associated with the use of ketek tablets or any macrolide antibiotic ketek is contraindicated in patients with a history of hypersensitivity to telithromycin andor any components of ketek tablets or any macrolide antibiotic concomitant administration of ketek with cisapride or pimozide is contraindicated see clinical pharmacology drugdrug interactions precautions concomitant administration of ketek and colchicine is contraindicated in patients with renal or hepatic impairment see warnings drug interactions precautions drug interactions,",1
"active hepatic disease such as hepatitis and cirrhosis is a contraindication for use of dantrolene sodium capsules dantrolene sodium capsules are contraindicated where spasticity is utilized to sustain upright posture and balance in locomotion or whenever spasticity is utilized to obtain or maintain increased function,",1
"isoniazid is contraindicated in patients who develop severe hypersensitivity reactions including druginduced hepatitis previous isoniazidassociated hepatic injury severe adverse reactions to isoniazid such as drug fever chills arthritis and acute liver disease of any etiology,",1
"mavenclad is contraindicated in patients with current malignancy see warnings and precautions 51 in pregnant women and in women and men of reproductive potential who do not plan to use effective contraception during mavenclad dosing and for 6 months after the last dose in each treatment course may cause fetal harm see warnings and precautions 52 use in specific populations 81 83 in patients infected with the human immunodeficiency virus hiv see warnings and precautions 54 in patients with active chronic infections eg hepatitis or tuberculosis see warnings and precautions 54 in patients with a history of hypersensitivity to cladribine see warnings and precautions 58 in women intending to breastfeed on a mavenclad treatment day and for 10 days after the last dose see use in specific populations 82 patients with current malignancy 4 pregnant women and women and men of reproductive potential who do not plan to use effective contraception during mavenclad dosing and for 6 months after the last dose in each treatment course 4 83 hiv infection 4 active chronic infections eg hepatitis or tuberculosis 4 history of hypersensitivity to cladribine 4 58 women intending to breastfeed on a mavenclad treatment day and for 10 days after the last dose 4 82,",1
"nateglinide tablets are contraindicated in patients with 1 known hypersensitivity to the drug or its inactive ingredients 2 type 1 diabetes 3 diabetic ketoacidosis this condition should be treated with insulin,",1
"injectable midazolam in contraindicated in patients with a known hypersensitivity to the drug benzodiazepines are contraindicated in patients with acute narrowangle glaucoma benzodiazepines may be used in patiens with openangle glaucoma only if they are receiving appropriate therapy measurements of intraocular pressure in patients without eye disease show a moderate lowering following induction with midazolam patients with glaucoma have not been studied midazolam injection is not intended for intrathecal or epidural administration due to the presence of the preservative benzyl alcohol in the dosage form midazoalm injection is contraindicated for use in premature infants because the formulation contains benzyl alcohol seexa0 n warnings n none n ufeffprecautions pediatric use,",1
"urocit in patients with hyperkalemia or who have conditions predisposing them to hyperkalemia as a further rise in serum potassium concentration may produce cardiac arrest such conditions include chronic renal failure uncontrolled diabetes mellitus acute dehydration strenuous physical exercise in unconditioned individuals adrenal insufficiency extensive tissue breakdown or the administration of a potassiumsparing agent such as triamterene spironolactone or amiloride in patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying esophageal compression intestinal obstruction or stricture or those taking anticholinergic medication in patients with peptic ulcer disease because of its ulcerogenic potential in patients with active urinary tract infection with either ureasplitting or other organisms in association with either calcium or struvite stones the ability of urocit in patients with renal insufficiency glomerular filtration rate of less than 07 mlkgmin because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia patients with hyperkalemia or who have conditions predisposing them to hyperkalemia such conditions include chronic renal failure uncontrolled diabetes mellitus acute dehydration strenuous physical exercise in unconditioned individuals adrenal insufficiency extensive tissue breakdown 4 patients for whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract such as those suffering from delayed gastric emptying esophageal compression intestinal obstruction or stricture 4 patients with peptic ulcer disease 4 patients with active urinary tract infection 4 patients with renal insufficiency glomerular filtration rate of less than 07 mlkgmin 4,",1
"afrezza is contraindicated in patients with the following during episodes of hypoglycemia chronic lung disease such as asthma or chronic obstructive pulmonary disease copd because of the risk of acute bronchospasm warnings and precautions 51 hypersensitivity to regular human insulin or any of the afrezza excipients see warnings and precautions 57 during episodes of hypoglycemia 4 chronic lung disease such as asthma or chronic obstructive pulmonary disease 4 hypersensitivity to regular human insulin or any of the afrezza excipients 4,",1
"isoniazid is contraindicated in patients who develop severe hypersensitivity reactions including druginduced hepatitis previous isoniazidassociated hepatic injury severe adverse reactions to isoniazid such as drug fever chills arthritis and acute liver disease of any etiology,",0
"hypersensitivity to bromocriptine or to any of the excipients of bromocriptine mesylate tablets or capsules uncontrolled hypertension and sensitivity to any ergot alkaloids in patients being treated for hyperprolactinemia bromocriptine mesylate tablets and capsules should be withdrawn when pregnancy is diagnosed see precautions hyperprolactinemic states in the event that bromocriptine is reinstituted to control a rapidly expanding macroadenoma see precautions hyperprolactinemic statesand a patient experiences a hypertensive disorder of pregnancy the benefit of continuing bromocriptine must be weighed against the possible risk of its use during a hypertensive disorder of pregnancy when bromocriptine is being used to treat acromegaly prolactinoma or parkinson disease in patients who subsequently become pregnant a decision should be made as to whether the therapy continues to be medically necessary or can be withdrawn if it is continued the drug should be withdrawn in those who may experience hypertensive disorders of pregnancy including eclampsia preeclampsia or pregnancyinduced hypertension unless withdrawal of bromocriptine is considered to be medically contraindicated the drug should not be used during the postpartum period in women with a history of coronary artery disease and other severe cardiovascular conditions unless withdrawal is considered medically contraindicated if the drug is used in the postpartum period the patient should be observed with caution,",1
"carvedilol is contraindicated in the following conditions n bronchial asthma or related bronchospastic conditions deaths from status asthmaticus have been reported following single doses of carvedilol second or thirddegree av block sick sinus syndrome severe bradycardia unless a permanent pacemaker is in place patients with cardiogenic shock or who have decompensated heart failure requiring the use of intravenous inotropic therapy such patients should first be weaned from intravenous therapy before initiating carvedilol patients with severe hepatic impairment patients with a history of a serious hypersensitivity reaction eg stevensjohnson syndrome anaphylactic reaction angioedema to any component of this medication or other medications containing carvedilol none none none xa0 bronchial asthma or related bronchospastic conditions n n n 4 xa0 second or thirddegree av block n n n 4 xa0 sick sinus syndrome n n n 4 xa0 severe bradycardia unless permanent pacemaker in place n n n 4 xa0 patients in cardiogenic shock or decompensated heart failure requiring the use of iv inotropic therapy n n n 4 xa0 severe hepatic impairment n n n 24 4 xa0 history of serious hypersensitivity reaction eg stevensjohnson syndrome anaphylactic reaction angioedema to any component of this medication or other medications containing carvedilol n n n 4,",1
"known or suspected carcinoma of the prostate or the male breast carcinoma of the breast in females with hypercalcemia androgenic anabolic steroids may stimulate osteolytic bone resorption pregnancy because of possible masculinization of the fetus oxandrolone has been shown to cause embryotoxicity fetotoxicity infertility and masculinization of female animal offspring when given in doses 9 times the human dose nephrosis the nephrotic phase of nephritis hypercalcemia,",1
"hypersensitivity to acetazolamide or any excipients in the formulation since acetazolamide is a sulfonamide derivative cross sensitivity between acetazolamide sulfonamides and other sulfonamide derivatives is possible acetazolamide therapy is contraindicated in situations in which sodium andor potassium blood serum levels are depressed in cases of marked kidney and liver disease or dysfunction in suprarenal gland failure and in hyperchloremic acidosis it is contraindicated in patients with cirrhosis because of the risk of development of hepatic encephalopathy longterm administration of acetazolamide is contraindicated in patients with chronic noncongestive angleclosure glaucoma since it may permit organic closure of the angle to occur while the worsening glaucoma is masked by lowered intraocular pressure,",0
"none n known hypersensitivity to the product 41 marked anxiety tension or agitation 42 glaucoma 43 tics or a family history or diagnosis of tourette syndrome 44 do not use methylphenidate hydrochloride extendedrelease tablets in patients currently using or within 2 weeks of using an mao inhibitor 45 hypersensitivity reactions such as angioedema and anaphylactic reactions have been observed in patients treated with methylphenidate hydrochloride extendedrelease tablets therefore methylphenidate hydrochloride extendedrelease tablets are contraindicated in patients known to be hypersensitive to methylphenidate or other components of the product see adverse reactions 66 methylphenidate hydrochloride extendedrelease tablets are contraindicated in patients with marked anxiety tension and agitation since the drug may aggravate these symptoms methylphenidate hydrochloride extendedrelease tablets are contraindicated in patients with glaucoma methylphenidate hydrochloride extendedrelease tablets are contraindicated in patients with motor tics or with a family history or diagnosis of tourettes syndrome see adverse reactions 64 methylphenidate hydrochloride extendedrelease tablets are contraindicated during treatment with monoamine oxidase mao inhibitors and also within a minimum of 14 days following discontinuation of a mao inhibitor hypertensive crises may result see drug interactions 71,",1
"rivastigmine tartrate capsules are contraindicated in patients with none n known hypersensitivity to rivastigmine other carbamate derivatives or other components of the formulation see description 11 a previous history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis in the absence of negative allergy testing see warnings and precautions 52 none isolated cases of generalized skin reactions have been described in postmarketing experience see adverse reactions 62 none n known hypersensitivity to rivastigmine other carbamate derivatives or other components of the formulation 4 history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis in the absence of negative allergy testing 4 52 none,",0
"esmolol hydrochloride injection is contraindicated in patients with none n severe sinus bradycardia may precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest n n n n n n see warnings and precautions 52 heart block greater than first degree second or thirddegree atrioventricular block may precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest n n n n n n see warnings and precautions 52 sick sinus syndrome may precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest n n n n n n see warnings and precautions 52 decompensated heart failure may worsen heart failure cardiogenic shock may precipitate further cardiovascular collapse and cause cardiac arrest iv administration of cardiodepressant calciumchannel antagonists eg verapamil and esmolol hydrochloride in close proximity ie while cardiac effects from the other are still present fatal cardiac arrests have occurred in patients receiving esmolol hydrochloride and intravenous verapamil pulmonary hypertension may precipitate cardiorespiratory compromise hypersensitivity reactions including anaphylaxis to esmolol or any of the inactive ingredients of the product crosssensitivity between beta blockers is possible n severe sinus bradycardiaxa0n n n 4 heart block greater than first degreexa0n n n 4 sick sinus syndrome n n n 4 decompensated heart failurexa0n n n 4 cardiogenic shockxa0n n n 4 coadministration of iv cardiodepressant calciumchannel antagonists eg verapamil in close proximity to esmolol hydrochloridexa0n n n 4 7 pulmonary hypertension n n n 4 known hypersensitivity to esmolol n n n 4,",1
"esomeprazole magnesium is contraindicated in patients with known hypersensitivity to substituted benzimidazoles or to any component of the formulation hypersensitivity reactions may include anaphylaxis anaphylactic shock angioedema bronchospasm acute interstitial nephritis and urticaria for information about contraindications of antibacterial agents clarithromycin and amoxicillin indicated in combination with esomeprazole magnesium refer to the contraindications section of their package insertsn see adverse reactions n 6 none none patients with known hypersensitivity to proton pump inhibitors ppis angioedema and anaphylaxis have occurred n 4,",0
"do not initiate in patients with constipation 41 history of chronic or severe constipation or sequelae from constipation intestinal obstruction stricture toxic megacolon gastrointestinal perforation andor adhesions ischemic colitis impaired intestinal circulation thrombophlebitis or hypercoagulable state crohns disease or ulcerative colitis diverticulitis severe hepatic impairment 42 concomitant use of fluvoxamine 43 alosetron hydrochloride should not be initiated see warnings and precautions 51 alosetron hydrochloride is contraindicated in patients with a history of the following chronic or severe constipation or sequelae from constipation intestinal obstruction stricture toxic megacolon gastrointestinal perforation andor adhesions ischemic colitis impaired intestinal circulation thrombophlebitis or hypercoagulable state crohns disease or ulcerative colitis diverticulitis severe hepatic impairment concomitant administration of alosetron hydrochloride with fluvoxamine is contraindicated fluvoxamine a known strong inhibitor of cyp1a2 has been shown to increase mean alosetron plasma concentrations auc approximately 6fold and prolong the halflife by approximately 3fold see drug interactions 71,",1
"edetate calcium disodium should not be given during periods of anuria nor to patients with active renal disease or hepatitis,",1
"the use of liletta is contraindicated when one or more of the following conditions exist n pregnancy or suspected pregnancy none for use as postcoital contraception emergency contraception none congenital or acquired uterine anomaly including fibroids that distorts the uterine cavityxa0and would be incompatible with correct ius placement none acute pelvic inflammatory disease pid or endometritisxa0or a history of pid unless there has been a subsequent intrauterine pregnancy none infected abortion in the past 3 months none known or suspected uterine or cervical neoplasia none known or suspected breast cancer or other hormonesensitive cancer now or in the past none uterine bleeding of unknown etiology none untreated acute cervicitis or vaginitis including bacterial vaginosis known chlamydial or gonococcal cervical infection or other lower genital tract infections until infection is controlled xa0 none acute liver disease or liver tumor benign or malignant none conditions associated with increased susceptibility to pelvic infectionsxa0 see warnings and precautions n 54 none a previously inserted ius that has not been removed none hypersensitivity to any component of lilettaxa0 see adverse reactions n 62 n pregnancy or suspected pregnancy 4 none use for postcoital contraception emergency contraception 4 none congenital or acquired uterine anomaly that distorts the uterine cavity andxa0would be incompatible with correct ius placement 4 none acute pelvic inflammatory disease pid or endometritisxa0or a history of pid unless there has been a subsequent intrauterine pregnancy 4 none infected abortion in the past 3 months 4 none known or suspected uterine or cervical neoplasiaxa0 4 none known or suspected breast cancer or other hormonesensitive cancer 4 none uterine bleeding of unknown etiology 4 none untreated acute cervicitis or vaginitisxa0or other lower genital tract infections 4 none acute liver disease or liver tumor benign or malignant 4 none increased susceptibility to pelvic infections 4 none a previously inserted ius that has not been removed 4 none hypersensitivity to any component of liletta 4,",1
"hypersensitivity 41 pregnancy unless used for treatment of advanced breast cancer 42 anaphylactic reactions to zoladex have been reported in the medical literature zoladex is contraindicated in those patients who have a known hypersensitivity to gnrh gnrh agonist analogues or any of the components in zoladex see warnings and precautions 56 zoladex is contraindicated during pregnancy unless zoladex is being used for palliative treatment of advanced breast cancer zoladex can cause fetal harm when administered to a pregnant woman if this drug is used during pregnancy the patient should be apprised of the potential hazard to the fetus there is an increased risk for pregnancy loss due to expected hormone changes that occur with zoladex treatment see use in specific populations 81,",2
"pregnancy 41 81 use of simvastatin or lovastatin and cyp3a substrates with narrow therapeutic range 42 concurrent longterm corticosteroid use 43 women with history of unexplained vaginal bleeding 44 women with endometrial hyperplasia with atypia or endometrial carcinoma 44 korlym is contraindicated in women who are pregnant pregnancy must be excluded before the initiation of treatment with korlym or if treatment is interrupted for more than 14 days in females of reproductive potential nonhormonal contraceptives should be used during and one month after stopping treatment in all women of reproductive potential see use in specific populations 88 korlym is contraindicated in patients taking simvastatin lovastatin and cyp3a substrates with narrow therapeutic ranges such as cyclosporine dihydroergotamine ergotamine fentanyl pimozide quinidine sirolimus and tacrolimus due to an increased risk of adverse events see drug interactions 71 123 korlym is contraindicated in patients who require concomitant treatment with systemic corticosteroids for serious medical conditions or illnesses eg immunosuppression after organ transplantation because korlym antagonizes the effect of glucocorticoids korlym is contraindicated in the following women with a history of unexplained vaginal bleeding women with endometrial hyperplasia with atypia or endometrial carcinoma korlym is contraindicated in patients with prior hypersensitivity reactions to mifepristone or to any of the product components,",1
"a patients exhibiting idiosyncratic reactions to psoralen compounds b patients possessing a specific history of light sensitive disease states should not initiate methoxsalen therapy except under special circumstances diseases associated with photosensitivity include lupus erythematosus porphyria cutanea tarda erythropoietic protoporphyria variegate porphyria xeroderma pigmentosum and albinism c patients with melanoma or with a history of melanoma d patients with invasive squamous cell carcinomas e patients with aphakia because of the significantly increased risk of retinal damage due to the absence of lenses,",1
"lorazepam injection is contraindicated in patients with a known sensitivity to benzodiazepines or its vehicle polyethylene glycol propylene glycol and benzyl alcohol in patients with acute narrowangle glaucoma or in patients with sleep apnea syndrome it is also contraindicated in patients with severe respiratory insufficiency except in those patients requiring relief of anxiety andor diminished recall of events while being mechanically ventilated the use of lorazepam injection intraarterially is contraindicated because as with other injectable benzodiazepines inadvertent intraarterial injection may produce arteriospasm resulting in gangrene which may require amputation see warnings lorazepam injection is contraindicated for use in premature infants because the formulation contains benzyl alcohol see  warnings precautions pediatric use,",2
"do not administer in the presence of diseases characterized by bleeding diathesis individuals with autoimmune disease may be at risk of exacerbating symptoms of the underlying disease possibly due to routine immunization patients who have experienced a recent myocardial infarction may not be tolerant of immunotherapy children with nephrotic syndrome probably should not receive injections due to immunization causing exacerbation of nephrotic disease,",1
"verapamil hydrochloride injection is contraindicated in 1 severe hypotension or cardiogenic shock 2 second or thirddegree av block except in patients with a functioning artificial ventricular pacemaker 3 sick sinus syndrome except in patients with a functioning artificial ventricular pacemaker 4 severe congestive heart failure unless secondary to a supraventricular tachycardia amenable to verapamil therapy 5 patients receiving intravenous betaadrenergic blocking drugs eg propranolol intravenous verapamil and intravenous betaadrenergic blocking drugs should not be administered in close proximity to each other within a few hours since both may have a depressant effect on myocardial contractility and av conduction 6 patients with atrial flutter or atrial fibrillation and an accessory bypass tract eg wolff parkinsonwhite lownganonglevine syndromes are at risk to develop ventricular tachyarrhythmia including ventricular fibrillation if verapamil is administered therefore the use of verapamil in these patients is contraindicated 7 ventricular tachycardia administration of intravenous verapamil to patients with widecomplex ventricular tachycardia qrs 012 sec can result in marked hemodynamic deterioration and ventricular fibrillation proper pretherapy diagnosis and differentiation from widecomplex supraventricular tachycardia is imperative in the emergency room setting 8 known hypersensitivity to verapamil hydrochloride,",1
"lindane shampoo is contraindicated in premature infants and individuals with known uncontrolled seizure disorders lindane shampoo is contraindicated for premature infants because their skin may be more permeable than that of full term infants and their liver enzymes may not be sufficiently developed to metabolize lindane lindane shampoo is also contraindicated for patients with crusted norwegian scabies and other skin conditions eg atopic dermatitis psoriasis that may increase systemic absorption of the drug lindane shampoo is contraindicated for patients with known uncontrolled seizure disorders and for individuals with a known sensitivity to the product or any of its components,",1
"zinbryta is contraindicated in patients with preexisting hepatic disease or hepatic impairment including alt or ast at least 2 times the uln because zinbryta could exacerbate existing liver dysfunction see dosage and administration 23 51 a history of autoimmune hepatitis or other autoimmune condition involving the liver see warnings and precautions 51 a history of hypersensitivity to daclizumab or any other components of the formulation use in such patients may result in anaphylaxis or lifethreatening multiorgan hypersensitivity see warnings and precautions 54 preexisting hepatic disease or hepatic impairment including alt or ast at least 2 times the uln 4 history of autoimmune hepatitis or other autoimmune condition involving the liver 4 history of hypersensitivity to daclizumab or any other component of the formulation 4,",1
"advanced arteriosclerosis symptomatic cardiovascular disease moderate to severe hypertension hyperthyroidism known hypersensitivity or idiosyncrasy to the sympathomimetic amines glaucoma none agitated states patients with a history of drug abuse known hypersensitivity or idiosyncrasy to amphetamine in patients known to be hypersensitive to amphetamine or other components of dextroamphetamine sulfate extendedrelease capsules hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products see n adverse reactions patients taking monoamine oxidase inhibitors maois or within 14 days of stopping maois including maois such as linezolid or intravenous methylene blue because of an increased risk of hypertensive crisis seexa0 n warnings xa0and n drug interactions,",1
"glyburide tablets are contraindicated in patients with known hypersensitivity the drug or any of its excipients diabetic ketoacidosis with or without coma this condition should be treated with insulin type i diabetes mellitus concomitant administration of bosentan warnings special warning on increased risk of cardiovascular mortality the administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin this warning is based on the study conducted by the university group diabetes program ugdp a longterm prospective clinical trial designed to evaluate the effectiveness of glucoselowering drugs in preventing or delaying vascular complications in patients with noninsulindependent diabetes the study involved 823 patients who were randomly assigned to one of four treatment groups ugdp reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide 15 grams per day had a rate of cardiovascular mortality approximately 2 times that of patients treated with diet alone a significant increase in total mortality was not observed but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality thus limiting the opportunity for the study to show an increase in overall mortality despite controversy regarding the interpretation of these results the findings of the ugdp study provide an adequate basis for this warning the patient should be informed of the potential risks and advantages of glyburide tablets and of alternative modes of therapy although only one drug in the sulfonylurea class tolbutamide was included in this study it is prudent from a safety standpoint to consider that this warning may also apply to other oral hypoglycemic drugs in this class in view of their close similarities in mode of action and chemical structure,",1
"lotemax ointment as with other ophthalmic corticosteroids is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis dendritic keratitis vaccinia and varicella and also in mycobacterial infection of the eye and fungal diseases of ocular structures lotemax ointment as with other ophthalmic corticosteroids is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis dendritic keratitis vaccinia and varicella and also in mycobacterial infection of the eye and fungal diseases of ocular structures 4,",1
"methazolamide tablets therapy is contraindicated in situations in which sodium andor potassium serum levels are depressed in cases of marked kidney or liver disease or dysfunction in adrenal gland failure and in hyperchloremic acidosis in patients with cirrhosis use may precipitate the development of hepatic encephalopathy none longterm administration of methazolamide is contraindicated in patients with angleclosure glaucoma since organic closure of the angle may occur in spite of lowered intraocular pressure,",1
"vexol 1 rimexolone ophthalmic suspension is contraindicated in epithelial herpes simplex keratitis dendritic keratitis vaccinia varicella and most other viral diseases of the cornea and conjunctiva mycobacterial infection of the eye fungal diseases of the eye acute purulent untreated infections which like other diseases caused by microorganisms may be masked or enhanced by the presence of the steroid and in those persons with hypersensitivity to any component of the formulation,",1
"eletriptan hydrobromide tablets are contraindicated in patients with none n ischemic coronary artery disease cad angina pectoris history of myocardial infarction or documented silent ischemia or coronary artery vasospasm including prinzmetal angina see warnings and precautions 51 wolffparkinsonwhite syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders see warnings and precautions 52 history of stroke transient ischemic attack tia or history or current evidence of hemiplegic or basilar migraine because these patients are at a higher risk of stroke see warnings and precautions 54 peripheral vascular disease see warnings and precautions 55 ischemic bowel disease see warnings and precautions 55 uncontrolled hypertension see warnings and precautions 58 recent use ie within 24 hours of another 5hydroxytryptamine 1 1 see drug interactions 71 hypersensitivity to eletriptan hydrobromide tablets angioedema and anaphylaxis seen see warnings and precautions 59 recent use ie within at least 72 hours of the following potent cyp3a4 inhibitors ketoconazole itraconazole nefazodone troleandomycin clarithromycin ritonavir or nelfinavir see drug interactions 72 and clinical pharmacology 123 n history of coronary artery disease cad or coronary artery vasospasm 4 wolffparkinsonwhite syndrome or other cardiac accessory conduction pathway disorders 4 history of stroke transient ischemic attack or history or current evidence of hemiplegic or basilar migraine 4 peripheral vascular disease 4 ischemic bowel disease 4 uncontrolled hypertension 4 within 24 hours of treatment with another 5ht 1 4 hypersensitivity to eletriptan hydrobromide tablets angioedema and anaphylaxis seen 4 within at least 72 hours of treatment with the following potent cyp3a4 inhibitors ketoconazole itraconazole nefazodone troleandomycin clarithromycin ritonavir or nelfinavir 4,",1
"active hepatic disease such as hepatitis and cirrhosis is a contraindication for use of dantrolene sodium capsules dantrolene sodium capsules are contraindicated where spasticity is utilized to sustain upright posture and balance in locomotion or whenever spasticity is utilized to obtain or maintain increased function,",1
"hypersensitivity ceftriaxone for injection is contraindicated in patients with known hypersensitivity to ceftriaxone any of its excipients or to any other cephalosporin patients with previous hypersensitivity reactions to penicillin and other beta lactam antibacterial agents may be at greater risk of hypersensitivity to ceftriaxone see warnings  hypersensitivity neonates premature neonates ceftriaxone for injection is contraindicated in premature neonates up to a postmenstrual age of 41 weeks gestational age chronological age hyperbilirubinemic neonates hyperbilirubinemic neonates should not be treated with ceftriaxone for injection ceftriaxone can displace bilirubin from its binding to serum albumin leading to a risk of bilirubin encephalopathy in these patients neonates requiring calcium containing iv solutions ceftriaxone for injection is contraindicated in neonates 28 days if they require or are expected to require treatment with calciumcontaining iv solutions including continuous calcium containing infusions such as parenteral nutrition because of the risk of precipitation of ceftriaxonecalcium see clinical pharmacology warnings dosage and administration cases of fatal outcomes in which a crystalline material was observed in the lungs and kidneys at autopsy have been reported in neonates receiving ceftriaxone for injection and calcium containing fluids in some of these cases the same intravenous infusion line was used for both ceftriaxone for injection and calciumcontaining fluids and in some a precipitate was observed in the intravenous infusion line there have been no similar reports in patients other than neonates lidocaine intravenous administration of ceftriaxone solutions containing lidocaine is contraindicated when lidocaine solution is used as a solvent with ceftriaxone for intramuscular injection exclude all contraindications to lidocaine refer to the prescribing information of lidocaine,",0
"trospium chloride tablets are contraindicated in patients with none n urinary retention gastric retention uncontrolled narrowangle glaucoma known hypersensitivity to the drug or its ingredients angioedema rash and anaphylactic reaction have been reported none n trospium chloride tablets are contraindicated inntn n patients with urinary retention gastric retention or uncontrolled narrowangle glaucoma and in patients who are at risk for these conditions n 4 patients with known hypersensitivity n 4,",1
"anuria hepatic coma or precoma known allergy or hypersensitivity to metolazone,",1
"hypersensitivity to acetazolamide or any excipients in the formulation since acetazolamide is a sulfonamide derivative cross sensitivity between acetazolamide sulfonamides and other sulfonamide derivatives is possible acetazolamide therapy is contraindicated in situations in which sodium andor potassium blood serum levels are depressed in cases of marked kidney and liver disease or dysfunction in suprarenal gland failure and in hyperchloremic acidosis it is contraindicated in patients with cirrhosis because of the risk of development of hepatic encephalopathy longterm administration of acetazolamide is contraindicated in patients with chronic noncongestive angleclosure glaucoma since it may permit organic closure of the angle to occur while the worsening glaucoma is masked by lowered intraocular pressure,",1
"chenodiol is contraindicated in the presence of know hepatocyte dysfunction or bile ductal abnormalities such as intrahepatic cholestasis primary biliary cirrhosis or sclerosing cholangitits see warnings a gallbladder confirmed as nonvisualizing after two consecutive single doses of dye radiopaque stones or gallstone complications or compelling reasons for gallbladder surgery including unremitting acute cholecystitis cholangitis biliary obstruction gallstone pancreatitis or biliary gastrointestinal fistula pregnancy category x chenodiol may cause fetal harm when administered to a pregnant woman serious hepatic renal and adrenal lesions occurred in fetuses of female rhesus monkeys given 60 to 90 mgkgday 4 to 6 times the maximum recommended human dose mrhd from day 21 to day 45 of pregnancy hepatic lesions also occurred in neonatal baboons whose mothers had received 18 to 38 mgkg 1 to 2 times the mrhd all during pregnancy fetal malformations were not observed neither fetal liver damage nor fetal abnormalities occurred in reproduction studies in rats and hamsters no human data are available at this time chenodiol is contraindicated in women who are or may become pregnant if this drug is used during pregnancy or if the patient becomes pregnant while taking this drug the patient should be apprised of the potential hazard to the fetus,",1
"diltiazem hydrochloride injection is contraindicated in patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker patients with second or thirddegree av block except in the presence of a functioning ventricular pacemaker patients with severe hypotension or cardiogenic shock patients who have demonstrated hypersensitivity to the drug intravenous diltiazem and intravenous betablockers should not be administered together or in close proximity within a few hours patients with atrial fibrillation or atrial flutter associated with an accessory bypass tract such as in wpw syndrome or short pr syndrome as with other agents which slow av nodal conduction and do not prolong the refractoriness of the accessory pathway eg verapamil digoxin in rare instances patients in atrial fibrillation or atrial flutter associated with an accessory bypass tract may experience a potentially lifethreatening increase in heart rate accompanied by hypotension when treated with diltiazem hydrochloride injection as such the initial use of diltiazem hydrochloride injection should be if possible in a setting where monitoring and resuscitation capabilities including dc cardioversiondefibrillation are present see overdosage patients with ventricular tachycardia administration of other calcium channel blockers to patients with wide complex tachycardia qrs 012 seconds has resulted in hemodynamic deterioration and ventricular fibrillation it is important that an accurate pretreatment diagnosis distinguish wide complex qrs tachycardia of superventricular origin from that of ventricular origin prior to administration of diltiazem hydrochloride injection,",1
"orphenadrine citrate extendedrelease tablets are contraindicated in patients with glaucoma pyloric or duodenal obstruction stenosing peptic ulcers prostatic hypertrophy or obstruction of the bladder neck cardiospasm megaesophagus and myasthenia gravis orphenadrine citrate tablets are contraindicated in patients who have demonstrated a previous hypersensitivity to the drug,",1
"leflunomide tablets are contraindicated in patients with known hypersensitivity to leflunomide or any of the other components of leflunomide tablets leflunomide tablets can cause fetal harm when administered to a pregnant woman leflunomide when administered orally to rats during organogenesis at a dose of 15 mgkg was teratogenic most notably anophthalmia or microophthalmia and internal hydrocephalus the systemic exposure of rats at this dose was approximately 110 the human exposure level based on auc under these exposure conditions leflunomide also caused a decrease in the maternal body weight and an increase in embryolethality with a decrease in fetal body weight for surviving fetuses in rabbits oral treatment with 10 mgkg of leflunomide during organogenesis resulted in fused dysplastic sternebrae the exposure level at this dose was essentially equivalent to the maximum human exposure level based on auc at a 1 mgkg dose leflunomide was not teratogenic in rats and rabbits when female rats were treated with 125 mgkg of leflunomide beginning 14 days before mating and continuing until the end of lactation the offspring exhibited marked greater than 90 decreases in postnatal survival the systemic exposure level at 125 mgkg was approximately 1100 the human exposure level based on auc leflunomide tablets are contraindicated in women who are or may become pregnant if this drug is used during pregnancy or if the patient becomes pregnant while taking this drug the patient should be apprised of the potential hazard to the fetus,",0
"durlaza is indicated to none n reduce the risk of death and myocardial infarction mi in patients with chronic coronary artery disease such as patients with a history of mi or unstable angina pectoris or with chronic stable angina reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack n n limitation of use durlaza is a nonsteroidal antiinflammatory drug indicated to reduce the risk of death and myocardial infarction mi in patients with chronic coronary artery disease such as patients with a history of mi or unstable angina pectoris or with chronic stable angina and to reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attackxa0xa0 1 n limitation of use 1 xa04 none,",3
"innopran xlcontrol of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than one drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education program joint national committee on prevention detection evaluation and treatment of high blood pressure jncnumerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularlyelevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mmhg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension for example patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goalsome antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects eg on angina heart failure or diabetic kidney disease these considerations may guide selection of therapyinnopran xl is a beta adrenergic blocker indicated for the treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions 1limitation of use innopran xl is not indicated for the treatment of hypertensive emergencies 1,",3
"pernicious anemia both uncomplicated and accompanied by nervous system involvement dietary deficiency of vitamin b1212 malabsorption of vitamin b121212 inadequate secretion of intrinsic factor resulting from lesions that destroy the gastric mucosa ingestion of corrosives extensive neoplasia and a number of conditions associated with a variable degree of gastric atrophy such as multiple sclerosis certain endocrine disorders iron deficiency and subtotal gastrectomy total gastrectomy always produces vitamin b12structural lesions leading to vitamin b12 competition for vitamin b12the fish tapeworm diphyllobothrium latum absorbs huge quantities of vitamin b1212 inadequate utilization of vitamin b12 for the schilling test,",3
"captopril tablets usp are indicated for the treatment of hypertensionin using captopril tablets usp consideration should be given to the risk of neutropeniaagranulocytosis see warningscaptopril tablets usp may be used as initial therapy for patients with normal renal function in whom the risk is relatively low in patients with impaired renal function particularly those with collagen vascular disease captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs or have failed to respond satisfactorily to drug combinationscaptopril tablets usp are effective alone and in combination with other antihypertensive agents especially thiazidetype diuretics the blood pressure lowering effects of captopril and thiazides are approximately additivecaptopril tablets usp are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis the beneficial effect of captopril in heart failure does not require the presence of digitalis however most controlled clinical trial experience with captopril has been in patients receiving digitalis as well as diuretic treatmentcaptopril tablets usp are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction 40 and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patientscaptopril tablets usp are indicated for the treatment of diabetic nephropathy proteinuria 500 mgday in patients with type i insulindependent diabetes mellitus and retinopathy captopril tablets usp decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes death or need for renal transplantation or dialysisin considering use of captopril tablets usp it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks in addition ace inhibitors for which adequate data are available cause a higher rate of angioedema in black than in nonblack patients see warnings head and neck angioedema intestinal angioedema,",0
"felodipine extendedrelease tablets usp are indicated for the treatment of hypertension to lower blood pressure lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including felodipine control of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than 1 drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education program joint national committee on prevention detection evaluation and treatment of high blood pressure jnc numerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly elevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mmhg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension for example patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal some antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects eg on angina heart failure or diabetic kidney disease these considerations may guide selection of therapy felodipine extendedrelease tablets usp may be administered with other antihypertensive agents,",3
"felodipine extendedrelease tablets usp are indicated for the treatment of hypertension to lower blood pressure lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including felodipine control of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than 1 drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education program joint national committee on prevention detection evaluation and treatment of high blood pressure jnc numerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly elevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mmhg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension for example patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal some antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects eg on angina heart failure or diabetic kidney disease these considerations may guide selection of therapy felodipine extendedrelease tablets usp may be administered with other antihypertensive agents,",3
"in the treatment of parkinsonism rigidity and tremor relieved by the apparently selective depressant actionin the gastrointestinal tract to relieve pylorospasm hypertonicity of the small intestine and the hypermotility of the colonto relieve hypertonicity of the uterine muscleto relax the spasm of biliary and uretered colic and bronchial spasmto diminish the tone of the detrusor muscle of the urinary bladder in the treatment of urinary tract disordersto control the crying and laughing episodes in patients with brain lesionsin cases of closed head injuries which cause acetylcholine to be released or to be present in cerebrospinal fluid which in turn causes abnormal eeg patterns stupor and neurological signsin the management of peptic ulcerin anesthesia to control excessive salivation and bronchial secretionsto control rhinorrhea of acute rhinitis or hay feveras an antidote for pilocarpine physostigmine isoflurophate choline esters certain species of aminata and in cases of anticholinesterase insecticide poisoningin poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare nerve gases large doses of atropine relieve the muscarinelike symptoms and some of the centralnervoussystem manifestations adults suspected of contact with organic phosphorus insecticides of the parathion type should be given atropine sulfate 08 mg intramuscularly if an atropine effect is not apparent within thirty minutes or if definite symptoms of the poisoning occur nausea vomiting diarrhea pupillary constriction pulmonary edema fasciculations of eyelids and tongue jerky ocular movements and excessive sweating salivation and bronchial secretion atropine sulfate 2 mg should be given intramuscularly at hourly intervals until signs of atropinization are observed up to two or three times this dose 4 to 6 mg may be required in severe cases removing contaminated clothing washing the skin and commencing artificial respiration and supportive therapy are also indicated,",0
"eliquis is a factor xa inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation 11for the prophylaxis of deep vein thrombosis dvt which may lead to pulmonary embolism pe in patients who have undergone hip or knee replacement surgery 12for the treatment of dvt and pe and for the reduction in the risk of recurrent dvt and pe following initial therapy 131415eliquis eliquis is indicated for the prophylaxis of deep vein thrombosis dvt which may lead to pulmonary embolism pe in patients who have undergone hip or knee replacement surgery eliquis is indicated for the treatment of dvteliquis is indicated for the treatment of pe eliquis is indicated to reduce the risk of recurrent dvt and pe following initial therapy,",3
"fosinopril sodium tablets are indicated for the treatment of hypertension it may be used alone or in combination with thiazide diureticsfosinopril sodium tablets are indicated in the management of heart failure as adjunctive therapy when added to conventional therapy including diuretics with or without digitalis see dosage and administrationin using fosinopril sodium consideration should be given to the fact that another angiotensin converting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagenvascular disease available data are insufficient to show that fosinopril sodium does not have a similar risk see warningsin considering use of fosinopril sodium it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in non blacks in addition ace inhibitors for which adequate data are available cause a higher rate of angioedema in black than in nonblack patients see warnings head and neck angioedema and intestinal angioedema,",0
"n n n none n none none prophylaxis and treatment of venous thrombosis and its extension pulmonary embolism pe prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation af andor cardiac valve replacement reduction in the risk of death recurrent myocardial infarction mi and thromboembolic events such as stroke or systemic embolization after myocardial infarction n none n limitations of use warfarin sodium tablets usp have no direct effect on an established thrombus nor does it reverse ischemic tissue damage once a thrombus has occurred however the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae warfarin sodium is indicated for n prophylaxis and treatment of venous thrombosis and its extension pulmonary embolism 1 prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation andor cardiac valve replacement 1 reduction in the risk of death recurrent myocardial infarction and thromboembolic events such as stroke or systemic embolization after myocardial infarction 1 n limitation of use warfarin sodium tablets usp has no direct effect on an established thrombus nor does it reverse ischemic tissue damage 1,",3
"clopidogrel tablets are a p2y 12 acute coronary syndrome for patients with nonstsegment elevation acs unstable angina uanonstelevation myocardial infarction nstemi clopidogrel tablets have been shown to reduce the rate of myocardial infarction mi and stroke 11for patients with stelevation myocardial infarction stemi clopidogrel tablets have been shown to reduce the rate of mi and stroke 11recent mi recent stroke or established peripheral arterial disease clopidogrel tablets have been shown to reduce the rate of mi and stroke 12 clopidogrel tablets are indicated to reduce the rate of myocardial infarction mi and stroke in patients with nonstsegment elevation acs unstable angina uanonstelevation myocardial infarction nstemi including patients who are to be managed medically and those who are to be managed with coronary revascularization clopidogrel tablets should be administered in conjunction with aspirin clopidogrel clopidogrel tablets are indicated to reduce the rate of myocardial infarction mi and stroke in patients with nonstsegment elevation acs unstable angina uanonstelevation myocardial infarction nstemi including patients who are to be managed medically and those who are to be managed with coronary revascularization clopidogrel tablets should be administered in conjunction with aspirin clopidogrel clopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute stelevation myocardial infarction stemi who are to be managed medically clopidogrel tablets should be administered in conjunction with aspirinclopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute stelevation myocardial infarction stemi who are to be managed medically clopidogrel tablets should be administered in conjunction with aspirinclopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute stelevation myocardial infarction stemi who are to be managed medically clopidogrel tablets should be administered in conjunction with aspirinclopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute stelevation myocardial infarction stemi who are to be managed medically clopidogrel tablets should be administered in conjunction with aspirin in patients with established peripheral arterial disease or with a history of recent myocardial infarction mi or recent stroke clopidogrel tablets are indicated to reduce the rate of mi and stroke,",3
"n hypertension quinapril hydrochloride tablets are indicated for the treatment of hypertension it may be used alone or in combination with thiazide diuretics in using quinapril hydrochloride tablets consideration should be given to the fact that another angiotensinconverting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagen vascular disease available data are insufficient to show that quinapril hydrochloride tablets do not have a similar risk see warnings n angioedema in black patients black patients receiving ace inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to nonblacks it should also be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks none,",0
"none n hypertension none trandolapril tablets are indicated for the treatment of hypertension they nmay be used alone or in combination with other antihypertensive medication such nas hydrochlorothiazide in considering the use of trandolapril tablets it should be noted that in ncontrolled trials ace inhibitors for which adequate data are available cause a nhigher rate of angioedema in black than in nonblack patients see n warnings angioedema when using trandolapril tablets consideration should be given to the fact nthat another angiotensin converting enzyme inhibitor captopril has caused nagranulocytosis particularly in patients with renal impairment or ncollagenvascular disease available data are insufficient to show that ntrandolapril tablets do not have a similar risk see n warnings,",0
"ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease stroke peripheral vascular disease or diabetes that is accompanied by at least one other cardiovascular risk factor hypertension elevated total cholesterol levels low hdl levels cigarette smoking or documented microalbuminuria to reduce the risk of myocardial infarction stroke or death from cardiovascular causes ramipril capsules can be used in addition to other needed treatment such as antihypertensive antiplatelet or lipidlowering therapy ramipril capsules are indicated for the treatment of hypertension it may be used alone or in combination with thiazide diuretics in using ramipril capsules consideration should be given to the fact that another angiotensin converting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagenvascular disease available data are insufficient to show that ramipril capsules do not have a similar risk see warningsin considering use of ramipril capsules it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks in addition ace inhibitors for which adequate data are available cause a higher rate of angioedema in black than in nonblack patients see warnings angioedema,",0
"none enalapril maleate is indicated for the treatment of hypertension none enalapril maleate is effective alone or in combination with other antihypertensive agents especially thiazidetype diuretics the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive enalapril maleate is indicated for the treatment of symptomatic congestive heart failure usually in combination with diuretics and digitalis in these patients enalapril maleate improves symptoms increases survival and decreases the frequency of hospitalization see clinical pharmacology n heart failure mortality trials for details and limitations of survival trials in clinically stable asymptomatic patients with left ventricular dysfunction ejection fraction 35 percent enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure see clinical pharmacology n heart failure mortality trials for details and limitations of survival trials none none in using enalapril maleate consideration should be given to the fact that another angiotensin converting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagen vascular disease and that available data are insufficient to show that enalapril maleate does not have a similar risk see warnings none none in considering use of enalapril maleate it should be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks in addition it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks see warnings n head and neck angioedema,",0
"stable coronary artery diseaseperindopril erbumine tablets are indicated in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease such as antiplatelet antihypertensive or lipidlowering therapy hypertension perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension perindopril erbumine tablets may be used alone or given with other classes of antihypertensives especially thiazide diuretics when using perindopril erbumine tablets consideration should be given to the fact that another angiotensin converting enzyme inhibitor captopril has caused agranulocytosis particularly in patients with renal impairment or collagen vascular disease available data are insufficient to determine whether perindopril erbumine tablets has a similar potential see warningsin considering use of perindopril erbumine tablets it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks in addition it should be noted that black patients receiving ace inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to nonblacks see warnings head and neck angioedema,",0
"captopril tablets usp are indicated for the treatment of hypertensionin using captopril tablets usp consideration should be given to the risk of neutropeniaagranulocytosis see warningscaptopril tablets usp may be used as initial therapy for patients with normal renal function in whom the risk is relatively low in patients with impaired renal function particularly those with collagen vascular disease captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs or have failed to respond satisfactorily to drug combinationscaptopril tablets usp are effective alone and in combination with other antihypertensive agents especially thiazidetype diuretics the blood pressure lowering effects of captopril and thiazides are approximately additivecaptopril tablets usp are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis the beneficial effect of captopril in heart failure does not require the presence of digitalis however most controlled clinical trial experience with captopril has been in patients receiving digitalis as well as diuretic treatmentcaptopril tablets usp are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction 40 and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patientscaptopril tablets usp are indicated for the treatment of diabetic nephropathy proteinuria 500 mgday in patients with type i insulindependent diabetes mellitus and retinopathy captopril tablets usp decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes death or need for renal transplantation or dialysisin considering use of captopril tablets usp it should be noted that in controlled trials ace inhibitors have an effect on blood pressure that is less in black patients than in nonblacks in addition ace inhibitors for which adequate data are available cause a higher rate of angioedema in black than in nonblack patients see  warnings head and neck angioedema intestinal angioedema,",0
"ticlopidine hydrochloride tablets usp are indicated to reduce the risk of thrombotic stroke fatal or nonfatal in patients who have experienced stroke precursors and in patients who have had a completed thrombotic stroke because ticlopidine is associated with a risk of lifethreatening blood dyscrasias including thrombotic thrombocytopenic purpura ttp neutropeniaagranulocytosis and aplastic anemia see and ticlopidine should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy boxed warningwarningsas adjunctive therapy with aspirin to reduce the incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation see clinical trials,",0
"n history of cardiovascular disease eg coronary artery disease stroke arrhythmias congestive heart failure uncontrolled hypertension during or within 14 days following the administration of monoamine oxidase inhibitors hyperthyroidism glaucoma agitated states history of drug abuse pregnancy see n n n n use in specific populations 81 nursing see n n n n use in specific populations 83 known hypersensitivity or idiosyncrasy to the sympathomimetic amines n history of cardiovascular disease eg coronary artery disease stroke arrhythmias congestive heart failure uncontrolled hypertension n n n none 4 during or within 14 days following the administration of monoamine oxidase inhibitors n n n none 4 hyperthyroidism n n n none 4 glaucoma n n n none 4 agitated states n n n none 4 history of drug abuse n n n 4 pregnancy n n n 4 81 nursing n n n 4 83 known hypersensitivity or idiosyncrasy to the sympathomimetic amines n n n none none 4,",1
"retinoids may cause fetal harm when administered to a pregnant woman in rats tazarotene 005 gel administered topically 2 topically 2 de 024h 2 024h 2 as with other retinoids when tazarotene was given orally de 024h 2 024h 2 in a study of the effect of oral tazarotene on fertility and early embryonic development in rats decreased number of implantation sites decreased litter size decreased numbers of live fetuses and decreased fetal body weights all classic developmental effects of retinoids were observed when female rats were administered 2 mgkgday from 15 days before mating through gestation day 7 a low incidence of retinoidrelated malformations at that dose was reported to be related to treatment this dose produced an auc de 024h 2 024h 2 systemic exposure to tazarotenic acid is dependent upon the extent of the body surface area treated in patients treated topically over sufficient body surface area exposure could be in the same order of magnitude as in these orally treated animals although there may be less systemic exposure in the treatment of acne of the face alone due to less surface area for application tazarotene is a teratogenic substance and it is not known what level of exposure is required for teratogenicity in humans see clinical pharmacology pharmacokinetics there were thirteen reported pregnancies in patients who participated in clinical trials for topical tazarotene nine of the patients were found to have been treated with topical tazarotene and the other four had been treated with vehicle one of the patients who was treated with tazarotene cream elected to terminate the pregnancy for nonmedical reasons unrelated to treatment the other eight pregnant women who were inadvertently exposed to topical tazarotene during clinical trials subsequently delivered apparently healthy babies as the exact timing and extent of exposure in relation to the gestation times are not certain the significance of these findings is unknown tazorac precautions pregnancy teratogenic effects tazorac,",3
"prednisolone acetate ophthalmic suspension 1 is contraindicated in acute untreated purulent ocular infections in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis dendritic keratitis vaccinia and varicella and also in mycobacterial infection of the eye and fungal diseases of ocular structures prednisolone acetate ophthalmic suspension 1 is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids,",1
"eletriptan hydrobromide tablets are contraindicated in patients with none n ischemic coronary artery disease cad angina pectoris history of myocardial infarction or documented silent ischemia or coronary artery vasospasm including prinzmetal angina see warnings and precautions 51 wolffparkinsonwhite syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders see warnings and precautions 52 history of stroke transient ischemic attack tia or history or current evidence of hemiplegic or basilar migraine because these patients are at a higher risk of stroke see warnings and precautions 54 peripheral vascular disease see warnings and precautions 55 ischemic bowel disease see warnings and precautions 55 uncontrolled hypertension see warnings and precautions 58 recent use ie within 24 hours of another 5hydroxytryptamine 1 1 see drug interactions 71 hypersensitivity to eletriptan hydrobromide tablets angioedema and anaphylaxis seen see warnings and precautions 59 recent use ie within at least 72 hours of the following potent cyp3a4 inhibitors ketoconazole itraconazole nefazodone troleandomycin clarithromycin ritonavir or nelfinavir see drug interactions 72 and clinical pharmacology 123 n history of coronary artery disease cad or coronary artery vasospasm 4 wolffparkinsonwhite syndrome or other cardiac accessory conduction pathway disorders 4 history of stroke transient ischemic attack or history or current evidence of hemiplegic or basilar migraine 4 peripheral vascular disease 4 ischemic bowel disease 4 uncontrolled hypertension 4 within 24 hours of treatment with another 5ht 1 4 hypersensitivity to eletriptan hydrobromide tablets angioedema and anaphylaxis seen 4 within at least 72 hours of treatment with the following potent cyp3a4 inhibitors ketoconazole itraconazole nefazodone troleandomycin clarithromycin ritonavir or nelfinavir 4,",1
"this product should not be used in patients with primary glaucoma or a predisposition to narrow anterior chamber angle glaucoma this product should not be used in pediatric patients who have previously had a severe systemic reaction to atropine this product should not be used in those persons showing hypersensitivity to any component of this preparation,",1
"metoclopramide tablets are contraindicated metoclopramide tablets are contraindicated in patients with a history of tardive dyskinesia td or a dystonic reaction to metoclopramide see warnings and precautions 51 52 when stimulation of gastrointestinal motility might be dangerous eg in the presence of gastrointestinal hemorrhage mechanical obstruction or perforation when stimulation of gastrointestinal motility might be dangerous eg in the presence of gastrointestinal hemorrhage mechanical obstruction or perforation in patients with pheochromocytoma or other catecholaminereleasing paragangliomas metoclopramide tablets may cause a hypertensivepheochromocytoma crisis probably due to release of catecholamines from the tumor in patients with pheochromocytoma or other catecholaminereleasing paragangliomas metoclopramide tablets may cause a hypertensivepheochromocytoma crisis probably due to release of catecholamines from the tumor see warnings and precautions 55 in patients with epilepsy metoclopramide tablets may increase the frequency and severity of seizures in patients with epilepsy metoclopramide tablets may increase the frequency and severity of seizures see adverse reactions 6 in patients with hypersensitivity to metoclopramide reactions have included laryngeal and glossal angioedema and bronchospasm in patients with hypersensitivity to metoclopramide reactions have included laryngeal and glossal angioedema and bronchospasm see adverse reactions 6 history of td or dystonic reaction to metoclopramide 4 when stimulation of gastrointestinal motility might be dangerous 4 pheochromocytoma catecholaminereleasing paragangliomas 4 epilepsy 4 hypersensitivity to metoclopramide 4,",1
"naratriptan tablets are contraindicated in patients with ischemic coronary artery disease cad angina pectoris history of myocardial infarction or documented silent ischemia or coronary artery vasospasm including prinzmetals angina see warnings and precautions 51 wolffparkinsonwhite syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders see warnings and precautions 52 history of stroke or transient ischemic attack tia or history of hemiplegic or basilar migraine because such patients are at a higher risk of stroke see warnings and precautions 54 peripheral vascular disease see warnings and precautions 55 ischemic bowel disease see warnings and precautions 55 uncontrolled hypertension see warnings and precautions 58 recent use ie within 24 hours of another 5ht 1 agonist ergotaminecontaining medication ergottype medication such as dihydroergotamine or methysergide see drug interactions 71 72 hypersensitivity to naratriptan angioedema and anaphylaxis seen see warnings and precautions 59 severe renal or hepatic impairment see use in specific populations 86 87 clinical pharmacology 123 history of coronary artery disease or coronary artery vasospasm 4 wolffparkinsonwhite syndrome or other cardiac accessory conduction pathway disorders 4 history of stroke transient ischemic attack or hemiplegic or basilar migraine 4 peripheral vascular disease 4 ischemic bowel disease 4 uncontrolled hypertension 4 recent within 24 hours use of another 5ht 1 agonist eg another triptan or an ergotaminecontaining medication 4 hypersensitivity to naratriptan angioedema and anaphylaxis seen 4 severe renal or hepatic impairment 4,",1
"tradjenta is contraindicated in patients with a history of a hypersensitivity reaction to linagliptin such as anaphylaxis angioedema exfoliative skin conditions urticaria or bronchial hyperreactivity see warnings and precautions 54 and adverse reactions 61 history of hypersensitivity reaction to linagliptin such as anaphylaxis angioedema exfoliative skin conditions urticaria or bronchial hyperreactivity 4,",0
"orphenadrine citrate extendedrelease tablets are contraindicated in patients with glaucoma pyloric or duodenal obstruction stenosing peptic ulcers prostatic hypertrophy or obstruction of the bladder neck cardiospasm megaesophagus and myasthenia gravis orphenadrine citrate tablets are contraindicated in patients who have demonstrated a previous hypersensitivity to the drug,",1
"ursodiol capsules will not dissolve calcified cholesterol stones radiopaque stones or radiolucent bile pigment stones hence patients with such stones are not candidates for ursodiol capsules therapy patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis cholangitis biliary obstruction gallstone pancreatitis or biliarygastrointestinal fistula are not candidates for ursodiol capsules therapy allergy to bile acids,",1
"coadministration of ergotamine with potent cyp 3a4 inhibitors ritonavir nelfinavir indinavir erythromycin clarithromycin and troleandomycin has been associated with acute ergot toxicity ergotism characterized by vasospasm and ischemia of the extremities see precautions drug interactions see warnings cyp 3a4 inhibitors ergomar sublingual tablets may cause fetal harm when administered to pregnant women ergomar sublingual tablets are contraindicated in women who are or may become pregnant if this drug is used during pregnancy or if the patient becomes pregnant while taking this product the patient should be apprised of the potential hazard to the fetus peripheral vascular disease coronary heart disease hypertension impaired hepatic or renal function and sepsis hypersensitivity to any of the components,",1
"rivastigmine tartrate capsules are contraindicated in patients with none n known hypersensitivity to rivastigmine other carbamate derivatives or other components of the formulation see description 11 a previous history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis in the absence of negative allergy testing see warnings and precautions 52 none isolated cases of generalized skin reactions have been described in postmarketing experience see adverse reactions 62 none n known hypersensitivity to rivastigmine other carbamate derivatives or other components of the formulation 4 history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis in the absence of negative allergy testing 4 52 none,",0
"n ischemic heart disease coronary artery vasospasm or other significant underlying cardiovascular disease 41 cerebrovascular syndromes eg history of stroke or tia 42 peripheral vascular disease including ischemic bowel disease 43 uncontrolled hypertension 44 do not use almotriptan tablets within 24 hours of an ergotaminecontaining or ergottype medication or of another 5ht 1 45 46 hemiplegic or basilar migraine 47 known hypersensitivity to almotriptan tablets 48 do not use almotriptan tablets in patients with ischemic heart disease angina pectoris history of myocardial infarction or documented silent ischemia or in patients who have symptoms or findings consistent with ischemic heart disease coronary artery vasospasm including prinzmetals variant angina or other significant underlying cardiovascular disease see warnings and precautions 51 do not use almotriptan tablets in patients with cerebrovascular syndromes including but not limited to stroke of any type as well as transient ischemic attacks see warnings and precautions 53 do not use almotriptan tablets in patients with peripheral vascular disease including but not limited to ischemic bowel disease see warnings and precautions 54 none because almotriptan tablets may increase blood pressure do not use almotriptan tablets in patients with uncontrolled hypertension see warnings and precautions 57 do not use almotriptan tablets and ergotaminecontaining or ergotderived medications like dihydroergotamine ergotamine tartrate or methysergide within 24 hours of each other see drug interactions 71 almotriptan tablets and other 5ht 1 see warnings and precautions 51 52 do not use almotriptan tablets in patients with hemiplegic or basilar migraine almotriptan tabletsxa0are contraindicated in patients with known hypersensitivity to almotriptan or any of its inactive ingredients,",1
"mayzent is contraindicated in patients who have a cyp2c933 genotype see use in specific populations 86 and clinical pharmacology 125 in the last 6 months experienced myocardial infarction unstable angina stroke tia decompensated heart failure requiring hospitalization or class iii or iv heart failure presence of mobitz type ii seconddegree thirddegree av block or sick sinus syndrome unless patient has a functioning pacemaker see warnings and precautions 53 patients with a cyp2c933 genotype 4 in the last 6 months experienced myocardial infarction unstable angina stroke tia decompensated heart failure requiring hospitalization or class iiiiv heart failure 4 presence of mobitz type ii seconddegree thirddegree av block or sick sinus syndrome unless patient has a functioning pacemaker 4,",1
"allergy to any component of tubersol or an anaphylactic or other allergic reaction to a previous test of tuberculin ppd is a contraindication to the use of tubersol see description how supplied tubersol should not be administered to persons who have had a severe reaction eg necrosis blistering anaphylactic shock or ulcerations to a previous tst persons with documented active tuberculosis or a clear history of treatment for tb infection or disease 10 persons with extensive burns or eczema,",1
"do not administer in the presence of diseases characterized by bleeding diathesis individuals with autoimmune disease may be at risk of exacerbating symptoms of the underlying disease possibly due to routine immunization patients who have experienced a recent myocardial infarction may not be tolerant of immunotherapy children with nephrotic syndrome probably should not receive injections due to immunization causing exacerbation of nephrotic disease,",1
"metopirone is contraindicated in patients with adrenal cortical insufficiency or hypersensitivity to metopirone or to any of its excipients,",1
"neostigmine is contraindicated in patients with n known hypersensitivity to neostigmine methylsulfate known hypersensitivity reactions have included urticaria angioedema erythema multiforme generalized rash facial swelling peripheral edema pyrexia flushing hypotension bronchospasm bradycardia and anaphylaxisxa0 peritonitis or mechanical obstruction of the urinary or intestinal tracts n hypersensitivity to neostigmine 4 peritonitis or mechanical obstruction of urinary or intestinal tracts 4 none,",0
"hypersensitivity to bethanechol chloride tablets hyperthyroidism peptic ulcer latent or active bronchial asthma pronounced bradycardia or hypotension vasomotor instability coronary artery disease epilepsy and parkinsonism bethanechol chloride should not be employed when the strength or integrity of the gastrointestinal or bladder wall is in question or in the presence of mechanical obstruction when increased muscular activity of the gastrointestinal tract or urinary bladder might prove harmful as following recent urinary bladder surgery gastrointestinal resection and anastomosis or when there is possible gastrointestinal obstruction in bladder neck obstruction spastic gastrointestinal disturbances acute inflammatory lesions of the gastrointestinal tract or peritonitis or in marked vagotonia,",1
"carteolol is contraindicated in those individuals with bronchial asthma or with a history of bronchial asthma or severe chronic obstructive pulmonary disease see warnings warnings,",1
"ribavirin capsules may cause birth defects andor death of the exposed fetus ribavirin therapy is contraindicated for use in women who are pregnant or in men whose female partners are pregnant see warnings precautions information for patients pregnancy category x ribavirin capsules are contraindicated in patients with a history of hypersensitivity to ribavirin or any component of the capsule patients with autoimmune hepatitis must not be treated with combination ribavirinintron a therapy because using these medicines can make the hepatitis worse patients with hemoglobinopathies eg thalassemia major sicklecell anemia should not be treated with ribavirin capsules combination ribavirin capsulesintron a therapy must not be used by females who are pregnant or by males whose female partners are pregnant extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients taking combination ribavirin capsulesintron a therapy combination ribavirin capsulesintron a therapy should not be initiated until a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy females of childbearing potential and males must use two forms of effective contraception during treatment and during the 6 months after treatment has been concluded significant teratogenic andor embryocidal effects have been demonstrated for ribavirin in all animal species in which adequate studies have been conducted these effects occurred at doses as low as one twentieth of the recommended human dose of ribavirin capsules if pregnancy occurs in a patient or partner of a patient during treatment or during the 6 months after treatment stops physicians are encouraged to report such cases by calling the ribavirin pregnancy registry at 18005932214 see boxed contraindications and warnings see warnings ribavirin capsules in combination with intron a injection is contraindicated in patients with a history of hypersensitivity to ribavirin andor alpha interferon or any component of the capsule andor injection patients with autoimmune hepatitis must not be treated with combination ribavirin capsulesintron a therapy,",1
"active uveal inflammation most cases of angleclosure glaucoma without iridectomy due to the possibility of increasing angle block hypersensitivity to the active or inactive ingredients,",1
"propafenone hydrochloride is contraindicated in the following circumstances n heart failure none cardiogenic shock none sinoatrial atrioventricular and intraventricular disorders of impulse generation or conductionxa0eg sick sinus node syndrome av block in the absence of an artificial pacemaker none known brugada syndrome none bradycardia none marked hypotension none bronchospastic disorders or severe obstructive pulmonary disease none marked electrolyte imbalance n heart failure 4 cardiogenic shock 4 sinoatrial atrioventricular and intraventricular disorders of impulse generation or conduction in the absence of pacemaker 4 none known brugada syndrome 4 none bradycardia 4 marked hypotension 4 bronchospastic disorders and severe obstructive pulmonary disease 4 none marked electrolyte imbalance 4,",1
"hypersensitivity to doxepin hydrochloride inactive ingredients or other dibenzoxepines 41 coadministration with monoamine oxidase inhibitors maois do not administer if patient is taking maois or has used maois within the past two weeks 42 untreated narrow angle glaucoma or severe urinary retention 43 silenor is contraindicated in individuals who have shown hypersensitivity to doxepin hcl any of its inactive ingredients or other dibenzoxepines serious side effects and even death have been reported following the concomitant use of certain drugs with mao inhibitors do not administer silenor if patient is currently on maois or has used maois within the past two weeks the exact length of time may vary depending on the particular maoi dosage and duration of treatment silenor is contraindicated in individuals with untreated narrow angle glaucoma or severe urinary retention,",1
